Prof. Nazzareno Galiè - unibo.it€¦ ·

0

Prof. Nazzareno Galiè

Professore Ordinario di Cardiologia

Direttore Scuola di Specializzazione

Malattie dell'Apparato Cardiovascolare

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Policlinico di Sant’Orsola

CURRICULUM VITAE

FRONTESPIZIO

1

Prof. Nazzareno Galiè

Professore Ordinario di Cardiologia

Direttore Scuola di Specializzazione

Malattie dell'Apparato Cardiovascolare

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Policlinico di Sant’Orsola

CURRICULUM VITAE Dati Personali, Formazione, Formazione all’estero Pag.2 CARRIERA ACCADEMICA Pag.3 ATTIVITA’ DIDATTICA Pag.4 ATTIVITA’ DI RICERCA Pag.9 PRODUZIONE SCIENTIFICA E BIBLIOMETRIA - GENNAIO 2018 Pag.11 ATTIVITA’ ISTITUZIONALI Pag.12 ATTIVITA’ ASSISTENZIALI Pag.13 APPENDICE 1: PUBBLICAZIONI - 20 Gennaio 2018 Pag.14

2

Dati Personali Data di Nascita: 23 Maggio, 1956 Indirizzo: Dipartimento di Medicina Diagnostica, Specialistica e Sperimentale, Università di Bologna, via Massarenti 9, 40138 Bologna-Italy. Tel:+39-3386721805 Fax:+ 39-051-344859 E-mail: [email protected] Formazione

Laureato in Medicina e Chirurgia con lode, Luglio 1979, Università di Bologna.

Specializzazione in Cardiologia, Università di Bologna, Luglio 1983.

Specializzazione in Medicina dello Sport, Università di Bologna, Luglio 1987. Formazione all’estero

Royal Postgraduate Medical School, University of London, Hammersmith Hospital, London, U.K., Luglio1983.

Research Fellow in Cardiology, Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas U.S.A., Agosto 1984-Gennaio 1985.

3

CARRIERA ACCADEMICA

PROFESSORE ASSOCIATO PER IL SETTORE DISCIPLINARE MALATTIE DELL'APPARATO CARDIOVASCOLARE (MED/11) FACOLTÀ DI MEDICINA E CHIRURGIA Dal 20/01/2005 ai soli fini giuridici Dal 01/02/2005 al 31/01/2008

PROFESSORE ASSOCIATO CONFERMATO PER IL SETTORE DISCIPLINARE MALATTIE DELL'APPARATO CARDIOVASCOLARE (MED/11) FACOLTA DI MEDICINA E CHIRURGIA Dal 20/01/2008 ai soli fini giuridici Dal 01/02/2008 al 19/10/2011

PROFESSORE ASSOCIATO CONFERMATO PER IL SETTORE DISCIPLINARE MALATTIE DELL'APPARATO CARDIOVASCOLARE (MED/11) SETTORE CONCORSUALE 06/D! MALATTIE DELL'APPARATO CARDIOVASCOLARE E MALATTIE DELL'APPARATO RESPIRATORIO FACOLTÀ DI MEDICINA E CHIRURGIA Dal 20/10/2011 al 15/10/2012

PROFESSORE ASSOCIATO CONFERMATO PER IL SETTORE DISCIPLINARE MALATTIE DELL'APPARATO CARDIOVASCOLARE (MED/11) SETTORE CONCORSUALE 06/D1 MALATTIE DELL'APPARATO CARDIOVASCOLARE E MALATTIE DELL'APPARATO RESPIRATORIO DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE Dal 16/10/2012 al 04/03/2018.

PROFESSORE ORDINARIO PER IL SETTORE DISCIPLINARE MALATTIE DELL'APPARATO CARDIOVASCOLARE (MED/11) SETTORE CONCORSUALE 06/D1 MALATTIE DELL'APPARATO CARDIOVASCOLARE E MALATTIE DELL'APPARATO RESPIRATORIO DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE Dal 04/03/2018

SEGRETARIO della Scuola di Specializzazione in Malattie Dell’Apparato Cardiovascolare dell’Università di Bologna dal Novembre 2013

DIRETTORE della Scuola di Specializzazione in Malattie Dell’Apparato Cardiovascolare dell’Università di Bologna dal Dicembre 2016

DIRETTORE del Master Universitario in inglese sulle Malattie della Circolazione Polmonare (Master in Pulmonary Vascular Diseases) dell’Università di Bologna dall’ AA 2007-2008 a tuttora. Le 12 edizioni tuttora svolte hanno incluso 151 specialisti in Cardiologia, Pneumologia e Medicina Interna provenienti da 31 diverse nazioni.

DOCENTE di corsi nelle Scuole di Specializzazione Medica della Università di Bologna

VISITING PROFESSORSHIP LECTURE at Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK, 2016

VISITING PROFESSORSHIP LECTURE at Hannover Medical School, Hannover, Germany, 2017

CARDIOVASCULAR GRAND ROUND LECTURE at the Brigham and Women's Hospital, University of Harvard Medical School, Boston, USA, 2017

4

LECTIO MAGISTRALIS at Campus Benjamin Franklin, Charité Universitätsmedizin, Medical Department, Division of Cardiology, Berlin, Germany, 2018

ATTIVITA’ DIDATTICA Affidamento di insegnamenti del SSD MED/11 nei Corsi di studio di I, II e III livello Corsi di Studio di Primo Livello 56709 - L' INTERPRETAZIONE DEI SINTOMI CARDIOLOGICI: DALLA PRESENTAZIONE CLINICA ALLA DIAGNOSI - 1 cfu Scuola: Medicina e Chirurgia, Università di Bologna. Corso: Laurea Specialistica a ciclo unico in Medicina e chirurgia. AA 2005-2006, 2007-2008, 2008-2009, 2009-2010. 03780 - MALATTIE DELL'APPARATO CARDIOVASCOLARE - 2 cfu Scuola: Medicina e Chirurgia, Università di Bologna. Corso: Laurea Specialistica a ciclo unico in Odontoiatria e protesi dentaria. AA 2005-2006, 2007-2008, 2008-2009, 2009-2010, 2010-2011, 2011-2012, 2012-2013, 2013-2014, 2014-2015, 2015-2016, 2016-2017, 2017-2018. 38200 - LE LINEE-GUIDA IN CARDIOLOGIA - 2 cfu. Insegnamento in Italiano. Scuola: Medicina e Chirurgia, Università di Bologna. Corso: Laurea Specialistica a ciclo unico in Medicina e chirurgia. AA 2010-2011. 67370 - LINEE GUIDA IN CARDIOLOGIA - 2 cfu. Componente del corso integrato LE EMERGENZE E LE LINEE-GUIDA IN CARDIOLOGIA (C.I.). Insegnamento in Italiano. Scuola: Medicina e Chirurgia. Corso: Laurea Specialistica a ciclo unico in Medicina e chirurgia. AA 2011-2012. 01228 - CARDIOLOGIA - 1 cfu. Componente del corso integrato SCIENZE INTERDISCIPLINARI CLINICHE I (C.I.). Insegnamento in Italiano. Scuola: Medicina e Chirurgia. Corso: Laurea in Igiene dentale (abilitante alla professione sanitaria di igienista dentale). AA 2011-2012. 70829 - EMERGENZE CARDIOLOGICHE NELL'ADULTO - 1 cfu Componente del corso integrato EMERGENZE E LINEE GUIDA CARDIOLOGICHE NELL'ADULTO E NELL'ETÀ EVOLUTIVA C.I.. Insegnamento in Italiano. Scuola: Medicina e Chirurgia, Università di Bologna. Corso: Laurea Magistrale a ciclo unico in Medicina e chirurgia. AA 2013-2014, 2014-2015. 70830 - LINEE GUIDA CARDIOLOGICHE NELL'ADULTO - 1 cfu. Componente del corso integrato EMERGENZE E LINEE GUIDA CARDIOLOGICHE NELL'ADULTO E NELL'ETÀ EVOLUTIVA C.I. Insegnamento in Italiano. Scuola: Medicina e Chirurgia. Corso: Laurea Magistrale a ciclo unico in Medicina e chirurgia. 2012-2013, 2013-2014. 39450 - FISIOPATOLOGIA DELL'APPARATO CARDIOVASCOLARE 2 - 1 cfu. Componente del corso integrato INDAGINI ELETTROFISIOLOGICHE SPECIALI, NEURORIABILITAZIONE E ULTRASONOLOGIA (C.I.). Scuola: Medicina e Chirurgia, Università di Bologna, Corso: Laurea in Tecniche di neurofisiopatologia (abilitante alla professione sanitaria di tecnico di neurofisiopatologia). AA 2013-2014, 2014-2015.

5

08957 - MALATTIE CARDIOVASCOLARI (L-Z) (A) - 4 cfu. Componente del corso integrato MALATTIE CARDIOVASCOLARI E DELL'APPARATO RESPIRATORIO (C.I.). Scuola: Medicina e Chirurgia, Università di Bologna. Corso: Laurea Magistrale a ciclo unico in Medicina e chirurgia. AA 2013-2014, 2014-2015, 2015-2016, 2016-2017, 2017-2018. 78614 - EMERGENZE E LINEE GUIDA CARDIOLOGICHE NELL'ADULTO - 1 cfu Coordinatore del corso integrato EMERGENZE E LINEE GUIDA CARDIOLOGICHE NELL'ADULTO E NELL'ETÀ EVOLUTIVA C.I.- Scuola: Medicina e Chirurgia, Università di Bologna. Corso: Laurea Magistrale a ciclo unico in Medicina e chirurgia. AA 2015-2016, 2016-2017, 2017-2018. Corsi di studio di Terzo livello Scuola di Specializzazione in Malattie Dell’Apparato Cardiovascolare della Università di Bologna. (Incompleto) PROTOCOLLI TERAPEUTICI NELL'IPERTENSIONE POLMONARE ANNO IV. 2012-2014. FISIOPATOLOGIA CARDIOVASCOLARE ANNO IV. 2004-2008, 2010-2011, 2011-2012. FISIOPATOLOGIA CARDIOVASCOLARE IV ANNO IV. 2008-2011. MALATTIE DELL'APPARATO CARDIOVASCOLARE ANNO I. 2013-2014, 2014-2015 (1 CFU). MALATTIE CARDIOVASCOLARI ANNO I. 2011-2014. CORSO DI CLINICA E TERAPIA DELLE MALATTIE DELL'AP ANNO II. 2011-2014. CORSO DI FISIOPATOLOGIA E SEMEIOLOGIA CLINICA ES ANNO I. 2012-2014. MALATTIE DELL'APPARATO CARDIOVASCOLARE IV- DIDATTICA FRONTALE (MODULO). 2014-2015. CORSO INTEGRATO MALATTIE DELL'APPARATO CARDIOVASC ANNO V (Modulo). 2012-2014, 2014-2015. ATTIVITÀ CARATTERIZZANTI ELETTIVE PROFESSIONALIZZ ANNO V. 2012-2013. ATTIVITÀ PROFESSIONALIZZANTI DISCIPLINE DELLA TIPOLOGIA I CARDIOLOGIA ANNO I. 2009-2013. ATTIVITA' PROFESSIONALIZZANTI DELLA TIPOLOGIA I CARDIOLOGIA ANNO I. 2013-2014 (A). ATTIVITA' PROFESSIONALIZZANTI DELLA TIPOLOGIA I CARDIOLOGIA ANNO I. 2013-2014 (B). ATTIVITÀ PROFESSIONALIZZANTI MALATTIE DELL'APPARATO CARDIOVASCOLARE II. ANNO II. 2012-2013. Scuola di Specializzazione in Cardiochirurgia della Università di Bologna MALATTIE DELL'APPARATO CARDIOVASCOLARE 2 ANNO II. 2012-2014 (1 CFU). Scuola di Specializzazione in Chirurgia Toracica della Università di Bologna CARDIOLOGIA ANNO I. 2007-2008. MALATTIE DELL'APPARATO CARDIOVASCOLARE ANNO I. 2008-2009 (1CFU). CORSO DI FISIOPATOLOGIA E SEMEIOLOGIA CLINICA E STRUMENTALE DELL'APPARATO CARDIOVASCOLARE. 2011-2012, 2012-2013, 2013-2014 (1CFU).

6

CORSO DI CLINICA E TERAPIA DELLE MALATTIE DELL'APPARATO CARDIOVASCOLARE. 2011-2012, 2012-2013, 2013-2014, 2014-2015 (1 CFU). Scuola di Specializzazione in Gastroenterologia della Università di Bologna MALATTIE CARDIOVASCOLARI ANNO I. 2011-2014 (1 CFU). ATTIVITÀ PROFESSIONALIZZANTI AREA CLINICA COMUNE II ANNO II. 2012-2014. Scuola di Specializzazione in Malattie Dell’Apparato Digerente della Università di Bologna CARDIOLOGIA. 2014-2015 (1 CFU). Scuola di Specializzazione in Malattie dell’Apparato Respiratorio METODOLOGIA D'INDAGINE DEL CIRCOLO SANG.POLM. ANNO III Integrativo di MEDICINA INTERNA. 2003-2004, 2007-2008. Scuola di Specializzazione in Medicina Interna della Università di Bologna ANGIOLOGIA ANNO II. 2011-2014, 2014-2015 (1 CFU). MALATTIE DELL'APPARATO CARDIOVASCOLARE ANNO III. 2013-2014, 2014-2015 (1CFU). Scuola di Specializzazione in Reumatologia della Università di Bologna-1 CFU REUMATOLOGIA ANNO III. 2006-2010, 2011-2012 MALATTIE CARDIOVASCOLARI ANNO I. 2008-2009, 2011-2012, 2012-2013, 2013-2014 (1CFU). Alta Formazione DIRETTORE del MASTER UNIVERSITARIO in inglese sulle Malattie della Circolazione Polmonare (Master in Pulmonary Vascular Diseases) dall’ AA 2007 a tuttora. Le 12 edizioni tuttora svolte hanno incluso 151 specialisti in Cardiologia, Cardiologia Pediatrica, Pneumologia e Medicina Interna provenienti da 31 nazioni. Attività di didattica integrativa e di servizio agli studenti (Incompleto)

Relatore di 31 Tesi di Laurea in Medicina e Chirurgia, Università di Bologna.

Relatore di 17 Tesi di Specializzazione in Malattie dell’Apparato Cardiovascolare, Università di Bologna.

lncarico con Decreto rettorale di Tutor-Valutatore per i Tirocinanti-candidati all’esame di abilitazione alla professione di Medico-Chirurgo: valutati 30 candidati dal 2004

Tutor per studenti stranieri nell’ambito degli scambi SISM (Segretariato Italiano Studenti in Medicina - Sede Locale di Bologna) da diversi anni. Nell’anno 2015 sono stati seguiti 3 studenti stranieri.

TUTOR al COLLEGIO SUPERIORE della Università di Bologna

7

Attività didattica ed incarichi di insegnamento internazionali: Direttore/Responsabile dei seguenti corsi accreditati dall’ European Board for the Accreditation in Cardiology (EBAC) effettuati all’estero.

Corso: “PDE5 Inhibition: A New Treatment Regimen for PAH”, Stockholm, 2005 (1CME)

Corso: “A New Oral Therapy for Pulmonary Arterial Hypertension via PDE5 Inhibition”, Barcelona 2006 (1 CME)

Corso: “Identification and Management of Patients with Pulmonary Arterial Hypertension”, European Heart House, Sophia Antipolis, Nice, France 2006 (9 CME)

Corso: “Pulmonary Arterial Hypertension: Clinical Experiences and Scientific Evidences”, European Heart House, Sophia Antipolis, Nice, France, 2007 (9 CME)

Corso: “Pulmonary Arterial Hypertension: Clinical Experiences and Scientific Evidences”, European Heart House, Sophia Antipolis, Nice, France, 2008 (9 CME)

Corso:”Pulmonary Arterial Hypertension: Guidelines, Gaps in Evidence and Future Challenges”, European Heart House, Sophia Antipolis, Nice, France 2009 (9 CME)

Corso” Pulmonary Hypertension: Registries, Trials and annual G5 meeting”, European Heart House, Sophia Antipolis, Nice, France 2010 (9 CME)

Corso: Pulmonary Hypertension: “Gaps of knowledge, Gaps of Evidence, Gaps of Organisation and annual G5 meeting”, European Heart House, Sophia Antipolis, Nice, France 2011 (9 CME)

Corso: “Pulmonary Hypertension-Future expectations and annual G6 meeting”, European Heart House, Sophia Antipolis, Nice, France 2012 (9 CME)

Corso: “Pulmonary Hypertension:Challenging The 2015 PH Guidelines and annual G6 meeting.” European Heart House, Sophia Antipolis, Nice, France 2016 (9 CME)

Direttore/Responsabile dei seguenti corsi accreditati dall’ European Accreditation Council for Continuing Medical Education (EACCME) e/o dall’ European Board for the Accreditation in Cardiology (EBAC) effettuate presso l’Università di Bologna.

Corso: Pulmonary Hypertension by Clinical Cases, Bologna, Italy 2013 (9 CME by EBAC and EACME)

Corso: Pulmonary Hypertension Bologna 2013: question, recent trials, debates and clinical cases. Bologna, Italy 2013 (8 CME by EACME)

Corso: Pulmonary Hypertension by Clinical Cases, Bologna, Italy 2014 (9 CME by EACCME)

Corso: Pulmonary Hypertension Bologna 2014: a landscape change from new trials. Bologna, Italy 2014 (8 CME by EACCME)


Corso: Pulmonary Hypertension Bologna 2015: testing the new guidelines into clinical cases. Bologna, Italy 2015 (6 CME by EACCME)


Corso: Pulmonary Hypertension Bologna 2016: one year of guidelines, it is already time to improve them? Bologna, Italy 2016 (6 CME by EACCME)

Corso: : Pulmonary Hypertension by Clinical Cases, Bologna, Italy 2017 (9 CME by EACCME)

Corso: Pulmonary Hypertension Bologna 2017 how to proceed in the future? Bologna, Italy 2017 (8 CME by EACCME)

8

Incarichi di insegnamento in istituzioni internazionali

Corso tenuto presso la European Food Safety Authority (EFSA) – Parma Ottobre-Dicembre 2012.

Tutor di Research Fellows provenienti dall’estero finanziati con fondi internazionali:

Dr. Naushad Hirani, Calgary University, Canada, 2006-2007

Dr. Robert Dragu, Rambam Health Care Center, Haifa, Israel 2009 - 2010

Dr Shigefumi Fukui, University of Osaka Japan. European Respiratory Society Fellowship 2015-2016

Dr. Ana Torrents Vil, Valencia University, Ottobre-Novembre 2017

9

ATTIVITA’ DI RICERCA Organizzazione, direzione e coordinamento di centri o gruppi di ricerca: Membro del Consiglio Direttivo dell’Istituto Nazionale di Biostrutture e Biosistemi (Consorzio Interuniversitario) dal 2014 (http://www.inbb.it/) Attività svolte sotto l’egida della Commissione Europea o della Organizzazione Mondiale della Sanità

Direttore locale dell’ European program "Disposition to PPH" supported by the European Commission within the Framework-5 RTD projects, 2002-2005.

Direttore locale dell’ European program "PULMOTENSION" supported by the European Commission within the Framework-6 RTD projects, 2006-2008.

Official External Expert dell’ European Medicines Agency (EMA)

Membro della Global Alliance Against Chronic Respiratory Diseases GARD-WHO program on pulmonary hypertension in developing countries

Vice-chairman del Core Network Pulmonary Hypertension del programma European Reference Network – LUNG, sotto l’egida della Commissione Europea dal Dicembre 2016

Responsabile del Comitato Funzionale per le Linee-Guida e per la Best Practice of Care del programma ERN-Lung dal 2017 sotto l’egida della Commissione Europea

Coordinamento o partecipazione a gruppi di studio e task forces

Past-Chairman del gruppo di studio sulla circolazione polmonare della Società Italiana di Cardiologia

Past-Chairman del Working Group on Pulmonary Circulation and Right Ventricular Function della European Society of Cardiology

Past-Member dello Scientific Council of The European Society of Cardiology

Past member dello Scientific Leadership Council of the Pulmonary Hypertension Association (USA)

Chairman della Task Force for the Guidelines 2004, 2009 and 2015 on Pulmonary Hypertension of the European Society of Cardiology and European Respiratory Society

Membro della Task Force for the Guidelines 2008 and 2014 on Pulmonary Embolism of the European Society of Cardiology

Membro della Task Force for the Guidelines 2010 for the Management of Grown-Up Congenital Heart Disease of the European Society of Cardiology

Membro dell’Organising Committee di 4 consecutivi World Symposia in Pulmonary Hypertension (Venice 2003, Dana Point 2008, Nice 2013, Nice 2018).

Direzione o Partecipazione a Comitati Editoriali di Riviste Scientifiche:

International Associate Editor dell’ European Heart Journal

Membro del Board of Consulting Editors di Cardiovascular Research

Membro del Board degli Editori di Circulation Journal

Membro dell’Editorial Board di Minerva Cardioangiologica

Membro dell’Editorial Board dell’European Respiratory Journal

Associate Editor dell’International Journal of Cardiology

10

Revisore delle seguenti riviste scientifiche: Circulation, Circulation Journal, Cardiovascular Research, Italian Heart Journal, European Heart Journal, European Journal of Heart Failure, European Respiratory Journal, European Journal of Echocardiography, American Journal of Respiratory and Critical Care Medicine, The Medical Letter, Thorax, Respiratory Medicine, Drugs, Heart, Chest, Nature Cardiovascular Medicine, Nature Clinical Practice Rheumathology, Journal of Cardiovascular Medicine, Jama, The Journal of Rheumatology, Thrombosis and Hemostasis, The Scandinavian Journal of Clinical & Laboratory Investigation Conseguimento di Premi nazionali ed internazionali

Premio del Consiglio Nazionale delle Ricerche 1984.

Award "Rorer" of Clinical Pharmacology 1985.

Travel Award of The American Thoracic Society 2002.

Gold Medal of The Polish Society of Cardiology 2006.

Award 2009 of the Libyan Society of Cardiology Membro Onorario di Società Scientifiche

Scholar della Società Italiana di Cardiologia

Honorary Fellow of the Royal College of Physicians – United Kingdom

Honorary member of The Romanian Pulmonology Society

Honorary member of the Polish Society of Cardiology

Honorary member of the Turkish Society of Cardiology

Fellow della European Society of Cardiology

11

PRODUZIONE SCIENTIFICA E BIBLIOMETRIA AD AGOSTO 2018 SCOPUS (Agosto 2018): pubblicazioni citate = 250; citazioni totali = 33378; H-index = 72 Inclusione nella lista Thomson Reuters Highly Cited Researchers nel 2014 e 2016; Inclusione nella lista Clarivate Analytics Highly Cited Researchers nel 2017. La lista degli Highly Cited Researchers viene pubblicata annualmente da Web of Science – Clarivate Analytics (https://clarivate.com/hcr/). La metodologia con cui sono stati identificati i 3300 scienziati di tutte le discipline considerati come “The World’s Most Influential Scientific Minds” è riportata nel sito della agenzia di rating scientifico (https://clarivate.com/hcr/worlds-influential-scientific-minds). Solo altri due gruppi di ricerca della Alma Mater - Università di Bologna hanno ottenuto questo titolo negli anni considerati. La lista complessiva delle pubblicazioni fino ad agosto 2018 è riportata nella Appendice 1

Sintesi delle maggiori riviste:

Rivista IF* N Articoli** Commenti

New England Journal of Medicine 72 9 2 primo nome, 2 secondo nome

Lancet 48 4 1 primo nome

J American College of Cardiology 20 19 7 primo nome, 7 secondo nome, 1ultimo nome

European Heart Journal 20 21 11 primo nome, 2 secondo nome, 2 ultimo nome

Circulation 19 5 3 primo nome

*Approssimato all’unità **Escluse lettere Editore di tre supplementi di Peer Reviewed Journals:

- Prostacyclin: basic principles and clinical application in congestive heart failure and primary pulmonary hypertension. Introduction. Am J Cardiol, 1995; 75: 1A-73A

- Pulmonary Arterial Hypertension: Epidemiology, Pathobiology, Assessment, and Therapy. J Am Coll Cardiol 2004; 43:1S – 90S

- Updates in Pulmonary Hypertension. J Am Coll Cardiol 2013; 62:D1-D126

https://clarivate.com/hcr/

https://clarivate.com/hcr/worlds-influential-scientific-minds

12

ATTIVITA’ ISTITUZIONALI Membro della Commissione per l’Ammissione al corso di Laurea in Medicina e Chirurgia negli anni 2011 e 2015 Membro della Commissione per l’Ammissione al corso di Specializzazione in Malattie dell’Apparato Cardiovascolare per diversi anni Direttore della Scuola di Specializzazione in Malattie Dell’Apparato Cardiovascolare dal Dicembre 2016 Membro del Collegio dei Docenti del Dottorato di Ricerca in Scienze Mediche Specialistiche dei seguenti cicli: - Ciclo XXV 2009-2012 - Ciclo XXVI 2010-2013 - Ciclo XXVII 2011-2014 - Ciclo XXVIII 2012-2015 - Ciclo XXIX 2013-2016

Membro del Collegio dei Docenti del Dottorato di Ricerca in Scienze Cardio Nefro Toraciche dei seguenti cicli: - Ciclo XXX 2014-2017 - Ciclo XXXI 2015-2018 - Ciclo XXXII 2016-2019 - Ciclo XXXIII 2017-2020 Membro del gruppo di valutazione dei seguenti programmi di finanziamento del Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR)

PRIN 2010-2011

Future in Research 2012

Nomina nel Gruppo di Esperti della Valutazione (GEV) da parte dell'Agenzia Nazionale per la Valutazione del sistema Universitario e della Ricerca (ANVUR) per la Valutazione delle Qualità della Ricerca (VQR) per gli anni 2004 – 2010 e 2011 – 2014.

Membro del comitato organizzativo degli Incontri Scientifici del Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale — DIMES dell’Università di Bologna dal 2016 Membro del gruppo di valutazione (referee) dei programmi di finanziamento alla ricerca delle seguenti istituzioni internazionali -British Heart Foundation, UK, 2010, 2012, 2017 -University College London, National Institute for Healt Research, UK 2010 -National Heart and Lung Institute, Imperial College, UK, 2012 -National Children Research Center, UK, 2014 -European Research Council, Bruxelles, Belgium 2015 -Swiss National Science Foundation, Switzerland 2015, 2016 -The French national Program of Clinical research, France, 2015

13

ATTIVITA’ ASSISTENZIALI

Assistente di Cardiologia, Ospedale Militare di Bologna, 1981-1982.

Consulente Ospedale Militare di Bologna 1985-1994.

Assistente Istituto di Cardiologia, Ospedale Universitario di Bologna S. Orsola-Malpighi dal 1987.

Dirigente medico di primo livello Unità Operativa Complessa di Cardiologia, Ospedale Universitario di Bologna S. Orsola-Malpighi dal 1994

Caporeparto (reparto Donne) presso la Unità Operativa Complessa di Cardiologia, Ospedale Universitario di Bologna S. Orsola-Malpighi dal 2002. Il reparto era costituito da 26 posti letto. Dati anno 2014: 1198 pazienti dimessi e 1341 pazienti transitati.

Direttore Unità Operativa Semplice – Ipertensione Polmonare, Dipartimento ad attività Integrata Cardio-Toraco-Vascolare, Ospedale Universitario di Bologna S. Orsola-Malpighi dal 2005. Centro Hub ufficiale Regione Emilia-Romagna. Dati anno 2014: attrazione extra-regionale 59%, 2546 visite ordinarie, 660 visite in day hospital, 412 ricoveri ordinari, 664 procedure emodinamiche.

Sostituto ufficiale di Direzione Unità Operativa Complessa di Cardiologia, Ospedale Universitario di Bologna S. Orsola-Malpighi dal 20 marzo 2013

Coordinatore settore a Bassa Intensità di Cura del Polo Cardio-Toraco-Vascolare, Padiglione 23, Ospedale Universitario di Bologna S. Orsola dal dicembre 2015. Attualmente risultano attivati 58 posti letto.

Agosto 2018 Prof. Nazzareno Galie'

14

APPENDICE 1: PUBBLICAZIONI – 22 Agosto 2018

1.Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO,Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ,Simonneau G. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018. PubMed PMID: 29590122; PubMed Central PMCID: PMC5873992.

2. Burks M, Stickel S, Galiè N. Pulmonary Arterial Hypertension: Combination Therapy in Practice. Am J Cardiovasc Drugs. 2018 Aug;18(4):249-257. doi: 10.1007/s40256-018-0272-5. Review. PubMed PMID: 29511993; PubMed Central PMCID: PMC6028878.

3.McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galie N. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. J Am Coll Cardiol 2018;71(7):752-763. DOI: 10.1016/j.jacc.2017.12.010

4.Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L,

Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; Badimon L, Vranckx P, Agewall S, Andreotti F, Antman E, Barbato E, Bassand JP, Bugiardini R, Cikirikcioglu M, Cuisset T, De Bonis M, Delgado V, Fitzsimons D, Gaemperli O, Galiè N, Gilard M, Hamm CW, Ibanez B, Iung B, James S, Knuuti J, Landmesser U, Leclercq C, Lettino M, Lip G, Piepoli MF, Pierard L, Schwerzmann M, Sechtem U, Simpson IA, Uva MS, Stabile E, Storey RF, Tendera M, Van de Werf F, Verheugt F, Aboyans V, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Roithinger FX, Aliyev F, Stelmashok V, Desmet W, Postadzhiyan A, Georghiou GP, Motovska Z, Grove EL, Marandi T, Kiviniemi T, Kedev S, Gilard M, Massberg S, Alexopoulos D, Kiss RG, Gudmundsdottir IJ, McFadden EP, Lev E, De Luca L, Sugraliyev A, Haliti E, Mirrakhimov E, Latkovskis G, Petrauskiene B, Huijnen S, Magri CJ, Cherradi R, Ten Berg JM, Eritsland J, Budaj A, Aguiar CT, Duplyakov D, Zavatta M, Antonijevic NM, Motovska Z, Fras Z, Montoliu AT, Varenhorst C, Tsakiris D, Addad F, Aydogdu S, Parkhomenko A, Kinnaird T.ESC Scientific Document Group ; ESC Committee for Practice Guidelines (CPG) ; ESC National Cardiac Societies . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419. PubMed PMID: 28886622.

5.Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L,

Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018 Jan 1;53(1):34-78. doi: 10.1093/ejcts/ezx334. PubMed PMID: 29045581.

6.Valgimigli, Marco, Bueno, Héctor, Byrne, Robert A., Collet, Jean-Philippe, Costa, Francesco, Jeppsson, Anders, Jüni, Peter, Kastrati, Adnan, Kolh, Philippe, Mauri, Laura, Montalescot, Gilles, Neumann,

15

Franz-Josef, Petricevic, Mate, Roffi, Marco, Steg, Philippe Gabriel, Windecker, Stephan, Zamorano, José Luis, Levine, Colaborador adicional: Glenn N., Badimon, Revisores del documento: Lina, Vranckx, Pascal, Agewall, Stefan, Andreotti, Felicita, Antman, Elliott, Barbato, Emanuele, Bassand, Jean-Pierre, Bugiardini, Raffaele, Cikirikcioglu, Mustafa, Cuisset, Thomas, De Bonis, Michele, Delgado, Victora, Fitzsimons, Donna, Gaemperli, Oliver, Galiè, Nazzareno, Gilard, Martine, Hamm, Christian W., Ibáñez, Borja, Iung, Bernard, James, Stefan, Knuuti, Juhani, Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lip, Gregory, Piepoli, Massimo Francesco, Pierard, Luc, Schwerzmann, Markus, Sechtem, Udo, Simpson, Iain A., Uva, Miguel Sousa, Stabile, Eugenio, Storey, Robert F., Tendera, Michal, Van de Werf, Frans, Verheugt, Freek, Aboyans, Victor (2018). ActualizaciÃ³n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboraciÃ³n con la EACTS. REVISTA ESPAÑOLA DE CARDIOLOGÍA, vol. 71, p. 4242.e1-42.e58, ISSN: 0300-8932, doi: 10.1016/j.recesp.2017.11.014

7.Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z. PubMed PMID: 29307087.

8.Galiè N, Manes A, Dardi F, Palazzini M. Aiming at the appropriate target for the treatment of

pulmonary hypertension due to left heart disease. Eur Heart J. 2017 Dec 27. doi: 10.1093/eurheartj/ehx751. [Epub ahead of print] PubMed PMID: 29293952.

9.Klok FA, Ageno W, Barco S, Binder H, Brenner B, Duerschmied D, Empen K, Faggiano P, Ficker JH, Galiè

N, Ghuysen A, Held M, Heydenreich N, Huisman MV, Jiménez D, Kozak M, Lang IM, Lankeit M, Münzel T, Petris A, Pruszczyk P, Quitzau K, Schellong S, Schmidt KH, Stefanovic BS, Verschuren F, Wolf-Puetz A, Meyer G, Konstantinides SV; PEITHO-2 Investigators. Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thromb Haemost. 2017 Dec;117(12):2425-2434. doi: 10.1160/TH17-06-0434. Epub 2017 Dec 6. PubMed PMID:29212130.

10.Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI(2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2017 Oct 2. pii: S1053-2498(17)32039-9. doi: 10.1016/j.healun.2017.09.024. [Epub ahead of print] PubMed PMID: 29096938.

11.Saia F, Palazzini M, Taglieri N, Manes A, Dardi F, Rinaldi A, Gotti E, Galiè N. Reply: Left Main Extrinsic Compression in Pulmonary Arterial Hypertension: From Identification to Percutaneous Coronary Intervention Optimization. J Am Coll Cardiol. 2017 Nov 7;70(19):2460-2461. doi: 10.1016/j.jacc.2017.08.067. PubMed PMID: 29096819.

12.Palazzini M, Dardi F, Galiè N. Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply. Eur J Heart Fail. 2017 Oct 11. doi: 10.1002/ejhf.969. [Epub ahead of print] PubMed PMID: 29024373.

13.Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug 17;50(2). pii: 1602493. doi:10.1183/13993003.02493-2016. Print 2017 Aug. PubMed PMID: 28818881; PubMed Central PMCID: PMC5593379.

16

14.Galiè N, Saia F, Palazzini M, Manes A, Russo V, Bacchi Reggiani ML, Dall'Ara G, Monti E, Dardi F, Albini A, Rinaldi A, Gotti E, Taglieri N, Marrozzini C, Lovato L, Zompatori M, Marzocchi A. Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. J Am Coll Cardiol. 2017 Jun 13;69(23):2808-2817. doi: 10.1016/j.jacc.2017.03.597. PubMed PMID: 28595696.

15.Palazzini M, Dardi F, Manes A, Bacchi Reggiani ML, Gotti E, Rinaldi A, Albini A, Monti E, Galiè N. Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail. 2017 May 2. doi:10.1002/ejhf.860. [Epub ahead of print] PubMed PMID: 28464427.

16.Perros F, de Man FS, Bogaard HJ, Antigny F, Simonneau G, Bonnet S, Provencher S, Galiè N, Humbert M. Use of β-Blockers in Pulmonary Hypertension. Circ Heart Fail. 2017 Apr;10(4). pii: e003703. doi: 10.1161/CIRCHEARTFAILURE.116.003703. Review. PubMed PMID: 28364092.

17.Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039. PubMed PMID: 28335835.

18.Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi:10.1093/eurheartj/ehx025. PubMed PMID: 28329315; PubMed Central PMCID: PMC5400052.

19.Leone MB, Giannotta M, Palazzini M, Cefarelli M, Martìn Suàrez S, Gotti E, Bacchi Reggiani ML, Zompatori M, Galiè N. A new CT-score as index of hemodynamic changes in patients with chronic thromboembolic pulmonary hypertension. Radiol Med. 2017 Jul;122(7):495-504. doi: 10.1007/s11547-017-0750-x. Epub 2017 Mar 18. PubMed PMID: 28316030.

20.Galiè N, Denton CP, Dardi F, Manes A, Mazzanti G, Li B, Varanese L, Esler A, Harmon C, Palazzini M. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol. 2017 May 15;235:67-72. doi: 10.1016/j.ijcard.2017.02.094. Epub 2017 Feb 22. PubMed PMID: 28279499

21.Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. J Heart Lung Transplant. 2016 Dec 24. pii: S1053-2498(16)30472-7. doi: 10.1016/j.healun.2016.12.012. [Epub ahead of print] PubMed PMID: 28190787.

22.Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV,

Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2016 Dec 30. pii: annrheumdis-2016-210236. doi: 10.1136/annrheumdis-2016-210236. [Epub ahead of print] PubMed PMID: 28039187.

17

23.Rasciti E, Sverzellati N, Silva M, Casadei A, Attinà D, Palazzini M, Galiè N, Zompatori M. Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension. Radiol Med. 2016 Dec 26. doi: 10.1007/s11547-016-0714-6. [Epub ahead of print] PubMed PMID: 28025781.

24.Hoeper MM, Lam CS, Vachiery JL, Bauersachs J, Gerges C, Lang IM, Bonderman D, Olsson KM, Gibbs

JS, Dorfmuller P, Guazzi M, Galiè N, Manes A, Handoko ML, Vonk-Noordegraaf A, Lankeit M, Konstantinides S, Wachter R, Opitz C, Rosenkranz S. Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research†. Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093/eurheartj/ehw597. [Epub ahead of print] PubMed PMID: 28011705.

25.Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec;25(142):381-389. doi: 10.1183/16000617.0084-2016. Review. PubMed PMID: 27903660.

26.Maron BA, Galiè N. Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review. JAMA Cardiol. 2016 Dec 1;1(9):1056-1065. doi: 10.1001/jamacardio.2016.4471. PubMed PMID: 27851839; PubMed Central PMCID: PMC5177491.

27.Mehta S, Sastry BK, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau

G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. PubMed PMID: 27671974.

28.Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58]. Int J Cardiol. 2016 Nov 15;223:1072-1073. doi: 10.1016/j.ijcard.2016.08.333. PubMed PMID: 27623401.

29.Galiè N, Manes A, Palazzini M. The difficult diagnosis of pulmonary vascular disease in heart failure. Eur Respir J. 2016 Aug;48(2):311-4. doi: 10.1183/13993003.00854-2016. PubMed PMID: 27478188. Humbert M, Galie N. The Ten Commandments for 2015 European Society of Cardiology–European Respiratory Society Guidelines on Pulmonary Hypertension. Eur Heart J. 2016 Jan 1;37(1):5. PubMed PMID: 27099879.

30.Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M, Waterhouse B, Langley J, Galié N. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. J Heart Lung Transplant. 2016 May 6. pii: S1053-2498(16)30117-6. doi: 10.1016/j.healun.2016.04.013. [Epub ahead of print] PubMed PMID: 27282418.

31.Humbert M, Galie N. What's new in the European Society of Cardiology/European Respiratory Society Pulmonary Hypertension Guidelines? Eur Heart J. 2016 Jan 1;37(1):4-5. doi: 10.1093/eurheartj/ehv636. PubMed PMID: 26712889.

32.Hoeper M, McLaughlin V, Dalaan AMA, Satoh T, Galie N. Treatment of pulmonary hypertension. The

Lancet Respiratory Medicine 2016. DOI: http://dx.doi.org/10.1016/S2213-2600(15)00542-1

33.Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT,Zompatori M, Hoeper M. 2015 ESC/ERS

18

Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):177. doi:10.1016/j.rec.2016.01.002. PubMed PMID: 26837729.

34.Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, Elliott G, Asano K, Grünig E, Yan Y, Jing

ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016 Feb;4(2):129-37. doi: 10.1016/S2213-2600(15)00544-5. Epub 2016 Jan 19. PubMed PMID: 26795434.

35.Hoeper MM, Galiè N. Letter by Hoeper and Galiè Regarding Article, "Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients with Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study". Circ Cardiovasc Interv.2016 Jan;9(1):e003422. doi: 10.1161/CIRCINTERVENTIONS.115.003422. PubMed PMID: 26755573.

36.Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. Kardiol Pol. 2015;73(12):1127-206. doi: 10.5603/KP.2015.0242. Polish. PubMed PMID: 26727670.

37.Essop MR, Galie N, Badesch DB, Lalloo U, Mahomed AG, Naidoo DP, Ntsekhe M, Williams PG. Management of pulmonary hypertension. S Afr Med J. 2015 Jun;105(6):437-9. PubMed PMID: 26716153.

38.Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Williams PG, Beghetti M, Corris P, Pepke-Zaba J, Souza R, DeMets DL, Gomberg-Maitland M, Greenberg BH, Schulman S, Douketis J; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi:10.1056/NEJMoa1503184. PubMed PMID: 26699168.

39.Galiè N, Manes A, Palazzini M. GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension. Breathe (Sheff). 2015 Sep;11(3):233-6. doi: 10.1183/20734735.111115. PubMed PMID: 26634007; PubMed Central PMCID: PMC4666452.

40.Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. Improving patient outcomes in pulmonary hypertension. Eur Respir Rev. 2015 Dec;24(138):550-1. doi: 10.1183/16000617.0064-2015. PubMed PMID: 26621969.

41.Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015 Dec;46(6):1711-20. doi: 10.1183/13993003.00364-2015. Epub 2015 Oct 22. PubMed PMID: 26493786; PubMed Central PMCID: PMC4664609.

42.Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X, Miera O, Rosenzweig

EB, Efficace M, Kusic-Pajic A, Beghetti M. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using thepediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016 Jan 1;202:52-8. doi: 10.1016/j.ijcard.2015.08.080. Epub 2015 Aug 9. PubMed PMID: 26386921.

19

43.Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barberà J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol Ç, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Völler H, Luis Zamorano J. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1, 37 ):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. PubMed PMID: 26320113.

44.Galie N, Manes A, Palazzini M. Exercise training in pulmonary hypertension: improving performance but waiting for outcome. Eur Heart J. 2016 Jan 1;37(1):45-8. doi: 10.1093/eurheartj/ehv440. Epub 2015 Aug 27. PubMed PMID: 26319935.

45.Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi:10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum in: Eur Respir J. 2015 Dec;46(6):1855-6. PubMed PMID: 26318161.

46.Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44. doi:10.1056/NEJMoa1413687. PubMed PMID: 26308684.

47.Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs J, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Authors/Task Force Members. Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2015 Oct 14;36(39):2642. doi: 10.1093/eurheartj/ehu479. Epub 2015 Jul 28. PubMed PMID: 26224077.

48.Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015 Nov;34(11):1366-75. doi: 10.1016/j.healun.2015.05.025. Epub 2015 Jun 11. PubMed PMID: 26210752.

49.Cantoni S, Bianchi F, Galletti M, Olivi E, Alviano F, Galiè N, Ventura C. Occurring of In Vitro Functional

Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture. Stem Cells Int. 2015;2015:943671. doi: 10.1155/2015/943671. Epub 2015 May 6. PubMed PMID: 26064139; PubMed Central PMCID: PMC4438190.

20

50.Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, Albini A, Gotti E, Monti E, Bacchi Reggiani ML, Galiè N. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J. 2015 Aug;46(2):414-21. doi: 10.1183/09031936.00209914. Epub 2015 May 28. PubMed PMID: 26022952.

51.Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs J, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Authors/Task Force Members. Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2015 Oct 14;36(39):2666. doi:10.1093/eurheartj/ehv131. Epub 2015 Apr 20. PubMed PMID: 25896079.

52.Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant. 2015 Mar;34(3):338-47. doi: 10.1016/j.healun.2014.12.001. Epub 2014 Dec 12. PubMed PMID: 25703961.

53.Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéy JL. [Pulmonary hypertension in chronic lung diseases]. Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:142-52. Turkish. PubMed PMID: 25697041.

54.Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W. [Pulmonary hypertension due to left heart diseases]. Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:130-41. Turkish. PubMed PMID: 25697040.

55.Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.[Updated treatment algorithm of pulmonary arterial hypertension]. Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:78-94. Turkish. PubMed PMID: 25697036.

56.Galiè N, Simonneau G. [The Fifth World Symposium on Pulmonary Hypertension]. Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:1-4. Turkish. PubMed PMID: 25697029.

57.Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015 May;45(5):1314-22. doi: 10.1183/09031936.00105914. Epub 2015 Feb 5. PubMed PMID: 25657022.

58.Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A,

Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a

long-term extension study (PATENT-2). Eur Respir J. 2015 Jan 22. pii: ERJ-00906-2014. [Epub ahead

of print] PubMed PMID: 25614164.

59.Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman M,

Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A,

Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M.

2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. Rev Esp

Cardiol (Engl Ed). 2015 Jan;68(1):64. doi: 10.1016/j.rec.2014.12.002. PubMed PMID: 25553941.

21

60.Attinà D, Niro F, Garzillo G, Modolon C, Russo V, Lovato L, Galiè N, Zompatori M. Thoracic

Manifestation of Eisenmenger's Syndrome in Adult Patients: A MDCT Review. Lung. 2014 Dec 31.

[Epub ahead of print] PubMed PMID: 25549894.

61.Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman M,


Pruszczyk P, Rasmussen LH, Schindler TH, Svítil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M.

[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. Kardiol

Pol. 2014;72(11):997-1053. doi: 10.5603/KP.2014.0211. Polish. PubMed PMID: 25524375.

62.Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ,

Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Effect of Macitentan on

Hospitalizations: Results From the SERAPHIN Trial. JACC Heart Fail. 2015 Jan;3(1):1-8. doi:

10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11. PubMed PMID: 25457902.

63.McLaughlin V, Simonneau G, Galiè N, Rubin LJ. New horizons in pulmonary arterial hypertension

management. Eur Respir Rev. 2014 Dec;23(134):408-9. doi: 10.1183/09059180.00007614. PubMed

PMID: 25445938.

64.Gatzoulis MA, Beghetti M, Landzberg MJ, Galiè N. Pulmonary arterial hypertension associated with

congenital heart disease: recent advances and future directions. Int J Cardiol. 2014 Dec

15;177(2):340-7. doi:10.1016/j.ijcard.2014.09.024. Epub 2014 Sep 28. PubMed PMID: 25443244.

65.Dragu R, Rispler S, Habib M, Sholy H, Hammerman H, Galie N, Aronson D. Pulmonary arterial

capacitance in patients with heart failure and reactive pulmonary hypertension. Eur J Heart Fail.

2014 Nov 11. doi: 10.1002/ejhf.192. [Epub ahead of print] PubMed PMID: 25388783.

66.Suissa S, Galié N. Letter by Suissa and Galié regarding article, "Anticoagulation and survival in

pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly

Initiated Therapies for Pulmonary Hypertension (COMPERA)". Circulation. 2014 Sep

16;130(12):e107. doi: 10.1161/CIRCULATIONAHA.113.007666. PubMed PMID: 25223777.

67.Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV,


Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M;

Authors/Task Force Members. 2014 ESC Guidelines on the diagnosis and management of acute

pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary

Embolism of the European Society of Cardiology (ESC)Endorsed by the European Respiratory

Society (ERS). Eur Heart J. 2014 Nov 14;35(43):3033-73. doi: 10.1093/eurheartj/ehu283. Epub 2014

Aug 29. PubMed PMID: 25173341.

68.Galletti M, Cantoni S, Zambelli F, Valente S, Palazzini M, Manes A, Pasquinelli G, Mai A, Galiè N,

Ventura C. Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell

proliferation and migration. BiochemPharmacol. 2014 Sep 15;91(2):181-90. doi:

10.1016/j.bcp.2014.07.011. Epub 2014 Jul 22. PubMed PMID: 25063234.

69.Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar

M, Layton GR, Sitbon O, Badesch DB; PACES Study Group. Long-term sildenafil added to

intravenous epoprostenol in patients with pulmonaryarterial hypertension. J Heart Lung

22

Transplant. 2014 Jul;33(7):689-97. doi:10.1016/j.healun.2014.02.019. Epub 2014 Feb 22. PubMed

PMID: 24815795.

70.Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J,Bluhmki E, Bouvaist H,

Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D,

Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A,

Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H,

Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with

intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. doi:

10.1056/NEJMoa1302097. PubMed PMID: 24716681.

71. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin

LJ. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary

arterial hypertension patients. Int J Cardiol. 2014 Mar 15;172(2):332-9. doi:

10.1016/j.ijcard.2013.12.179. Epub 2014 Jan 9. PubMed PMID: 24525158.

72.Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T,

Lemarié JC, Simonneau G. EPITOME-2: An open-label study assessing the transition to a new

formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am

Heart J. 2014 Feb;167(2):210-7.doi: 10.1016/j.ahj.2013.08.007. Epub 2013 Oct 3. PubMed PMID:

24439982.

73.Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV,

Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary

arterial hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-72. doi:

10.1016/j.jacc.2013.10.031. Review. PubMed PMID: 24355643.

74.Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs

S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL. Pulmonary hypertension in

chronic lung diseases. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi:


75.Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs

JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W. Pulmonary hypertension due to left

heart diseases. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8. doi:


76.Galiè N, Simonneau G. The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol.

2013 Dec 24;62(25 Suppl):D1-3. doi: 10.1016/j.jacc.2013.10.030. PubMed PMID: 24355633.

77.Mineo G, Attinà D, Mughetti M, Balacchi C, De Luca F, Niro F, Ciccarese F, Lovato L, Russo V, Buia F,

Modolon C, Manes A, Palazzini M, Galiè N, Zompatori M. Pulmonary veno-occlusive disease: the

role of CT. Radiol Med. 2013 Dec 3. [Epub ahead of print] PubMed PMID: 24297597.

78. Galiè N, Ghofrani AH. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev.

2013 Dec;22(130):503-14. doi: 10.1183/09059180.00006613. PubMed PMID: 24293466.

23

79.Rubin LJ, Galiè N, Simonneau G, McLaughlin V. A paradigm shift in pulmonary arterial hypertension

management. Eur Respir Rev. 2013 Dec;22(130):423-6. doi: 10.1183/09059180.00006913. PubMed

PMID: 24293459.

80. Rossi A, Zompatori M, Tchouante Tchouanhou P, Amadori M, Palazzini M, Conficoni E, Galiè N,

Poletti V, Gavelli G. Rare causes of pulmonary hypertension: spectrum of radiological findings and

review of the literature. Radiol Med. 2013 Nov 15. [Epub ahead of print] PubMed PMID: 24234182.

81.Saia F, Galiè N, Laborde JC, Di Bartolomeo R, Manes A, Marzocchi A. Transcatheter aortic valve

implantation for severe autograft regurgitation after Ross operation. EuroIntervention. 2013 Sep

16. pii: 20090910-01. [Epub ahead of print] PubMed PMID: 24035838.

82.Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO,

Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ,

Simonneau G; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary

arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

PubMed PMID: 23984728.

83.Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama

MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group.Riociguat for the treatment of pulmonary

arterial hypertension. N Engl J Med.2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.


84.Galiè N, Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J

Am Coll Cardiol. 2013 Sep 17;62(12):1101-2. doi: 10.1016/j.jacc.2013.06.032. Epub 2013 Jul 10.


85.Attinà D, Niro F, Tchouanté P, Mineo G, Russo V, Palazzini M, Galiè N, Fanti S, Lovato L, Zompatori

M. Pulmonary artery intimal sarcoma. Problems in the differential diagnosis. Radiol Med. 2013

Dec;118(8):1259-68. doi: 10.1007/s11547-013-0943-x. Epub 2013 Jun 25. PubMed PMID:

23801391.

86. Zompatori M, Leone MB, Giannotta M, Galiè N, Palazzini M, Reggiani ML, Bono L, Pollini GS.

Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography.

Radiol Med. 2013 Dec;118(8):1360-72. doi:10.1007/s11547-013-0934-1. Epub 2013 May 27.


87. Cantoni S, Galletti M, Zambelli F, Valente S, Ponti F, Tassinari R, Pasquinelli G, Galiè N, Ventura C.

Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in

pulmonary artery smooth muscle cells through Akt inhibition. FEBS J. 2013 May;280(9):2042-55.

doi: 10.1111/febs.12227. Epub 2013 Mar 28. PubMed PMID: 23463962.

88.Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients

with pulmonary arterial hypertension associated with congenital heart disease: a comparison

between clinical subgroups. Eur Heart J. 2014 Mar;35(11):716-24. doi: 10.1093/eurheartj/eht072.

Epub 2013 Mar 1. PubMed PMID: 23455361.

89.Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F,

Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F,

24

Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on therapy for pulmonary arterial

hypertension: results of the randomized IMPRES study. Circulation. 2013 Mar 12;127(10):1128-38.

doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12. PubMed PMID: 23403476.

90.Taglieri N, Galiè N, Marzocchi A. Acute hand ischemia after radial intervention in patient with CREST-

associated pulmonary hypertension: successful treatment with manual thromboaspiration. J

Invasive Cardiol. 2013 Feb;25(2):89-91. PubMed PMID: 23388228.

91.Nazzareno Galie, Alessandra Manes (2013). Malattie del circolo polmonare. In: (a cura di): Branzi A,

Picchio FM, Cardiologia. p. 407-447, Milano:MC Graw-Hill Education, ISBN: 9788838629082

92.Guazzi M, Galiè N. Pulmonary hypertension in left heart disease. Eur Respir Rev. 2012 Dec

1;21(126):338-46. doi: 10.1183/09059180.00004612. Review. PubMed PMID: 23204122.

93.Humbert M, Souza R, Galiè N, McLaughlin V, Simonneau G, Rubin L. Pulmonary arterial

hypertension: bridging the present to the future. Eur Respir Rev. 2012 Dec 1;21(126):267-70. doi:

10.1183/09059180.00005312. PubMed PMID: 23204116.

94.Galiè N, Rubin L, Simonneau G. Developing a heart score: next steps. Am J Cardiol. 2012 Sep

15;110(6 Suppl):49S-51S. doi: 10.1016/j.amjcard.2012.06.016. Review. PubMed PMID: 22921032.

95.Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M,

Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep

1;21(125):234-8. doi: 10.1183/09059180.00003712. Review. PubMed PMID: 22941888.

96. Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A,

Barst RJ; PHIRST Study Group. Tadalafil for the treatment of pulmonary arterial hypertension: a

double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012 Aug 21;60(8):768-74.

doi: 10.1016/j.jacc.2012.05.004. Epub 2012 Jul 18. PubMed PMID: 22818063.

97.Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM,

Laliberte K, Sigman J, Arneson C, Galiè N. Oral treprostinil for the treatment of pulmonary arterial

hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase

type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012

Dec;142(6):1383-90. doi: 10.1378/chest.11-2212. PubMed PMID: 22628490.

98.Manes A, Palazzini M, Dardi F, D'Adamo A, Rinaldi A, Galiè N. [Female gender and pulmonary

arterial hypertension: a complex relationship]. G Ital Cardiol (Rome). 2012 Jun;13(6):448-60. doi:

10.1714/1073.11764. Italian. PubMed PMID: 22622125.

99.De Luca F, Modolon C, Buia F, Attinà D, Fughelli P, Bacchi Reggiani ML, Galiè N, Zompatori M.

Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary

arteries before and after contrast injection. Radiol Med. 2012 Sep;117(6):979-91. Epub 2012 May

14. PubMed PMID: 22580809.

100.Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, Degano B, Bonderman D,

Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag: an oral, selective prostacyclin receptor

agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.

Epub 2012 Feb 23. PubMed PMID: 22362844.

25

101. Beghetti M, Galiè N, Bonnet D. Can "inoperable" congenital heart defects become operable in

patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis. 2012 Jan-

Feb;7(1):3-11. doi: 10.1111/j.1747-0803.2011.00611.x. Epub 2012 Jan 10. Review. PubMed PMID:

22233186.

102.Modolon C, Attinà D, Buia F, De Luca F, Fughelli P, Bacchi Reggiani ML, Palazzini M, Manes A, Leci E,

Galiè N, Zompatori M. Lung neovascularity in pulmonary arterial hypertension associated with

congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients. Eur

Radiol. 2012 May;22(5):1059-66. doi: 10.1007/s00330-011-2347-4. Epub 2011 Dec 30. PubMed

PMID: 22205444.

103.Konstantinides SV, Meyer G, Lang I, Verschuren F, Meyer G, Meneveau N, Charbonnier B, Bouvaist

H, Geibel A, Beyer-Westendorf J, Dellas C, Empen K, Kupatt C, Galiè N, Giancarlo, Becattini C, Salvi

A, Pruszczyk P, Torbicki A, Franca A, Lohmann C, Kozak M, Jiménez D, Kucher N, Goldha... ber SZ,

Danays T, Bluhmki E, Gallula P.. Single-bolus tenecteplase plus heparin compared with heparin

alone for normotensive patients with acute pulmonary embolism who have evidence of right

ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism

Thrombolysis (PEITHO) trial. Am Heart J. 2012 Jan;163(1):33-38.e1. doi: 10.1016/j.ahj.2011.10.003.


104.Nazzareno Galiè, Alessandra Manes, Massimiliano Palazzini (2012). Current medical therapies in

pulmonary arterial hypertension. In: (a cura di): Hoeper M, Humbert M, Pulmonary Hypertension.

p. 26-41, Sheffiled:European Respiratory Society, ISBN: 9781849840255 DOI:

10.1183/1025448x.10018611

105.Russo V, Zompatori M, Galiè N. Extensive right pulmonary artery dissection in a young patient with

chronic pulmonary hypertension. Heart. 2012 Feb;98(3):265-6. doi: 10.1136/heartjnl-2011-301132.

Epub 2011 Dec 10. PubMed PMID: 22155730.

106.Galie' N, Palazzini M, Manes A. (2012). Vasoactive intestinal peptide in pulmonary arterial

hypertension: Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol.

185, p. 786, ISSN: 1073-449X.

107.Helmut Baumgartner, Philipp Bonhoeffer, Natasja MS De Groot, Fokko de Haan, John Erik

Deanfield, Galie' N, Michael A Gatzoulis, Christa Gohlke-Baerwolf, Harald Kaemmerer, Philip Kilner,

Folkert Meijboom, Barbara JM Mulder, Erwin Oechslin, Jose M Oliver, Alain Serraf, Andras Szatmari,

Erik Thaulow, Pascal R Vouhe, Edmond Walma (2012). Recomendagoes da ESC para o tratamento

da cardiopatia congenita no adulto (nova versao de 2010): Grupo de Trabalho para o Tratamento

da Cardiopatia Congenita no Adulto da European Society of Cardiology (Sociedade Europeia de

Cardiologia)(ESC). REVISTA PORTUGUESA DE CARDIOLOGIA, vol. 31, p. 541-e1-541-e53, ISSN: 0870-

2551

108.Galié N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S,

Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M,

Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brenta... no C,

Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA,

Tendera M, Vardas P, Widimsky P. (2012). Guidelines for the diagnosis and treatment of pulmonary

hypertension Orientações para o diagnóstico e tratamento da hipertensão pulmonar. REVISTA

26

PORTUGUESA DE CARDIOLOGIA, vol. 31, p. 71-115, ISSN: 0870-2551, doi:

10.1016/j.repc.2011.12.002

109.Vonk Noordegraaf A, Galiè N. The role of the right ventricle in pulmonary arterial hypertension. Eur

Respir Rev. 2011 Dec;20(122):243-53. doi: 10.1183/09059180.00006511. Review. PubMed PMID:

22130817.

110.Lau EM, Manes A, Celermajer DS, Galiè N. Early detection of pulmonary vascular disease in

pulmonary arterial hypertension: time to move forward. Eur Heart J. 2011 Oct;32(20):2489-98. doi:

10.1093/eurheartj/ehr160. Epub 2011 May 26. Review. PubMed PMID: 21616950.

111. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G,

Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group. Long-term treatment with

sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011

Nov;140(5):1274-83. doi: 10.1378/chest.10-0969. Epub 2011 May 5. PubMed PMID: 21546436.

112.Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè N;

Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension

(EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-

blind, placebo-controlled study. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1723-9. doi:

10.1164/rccm.201101-0093OC. Epub 2011 Mar 11. PubMed PMID: 21471085.

113.Galiè N, Hoeper MM, Simon J, Gibbs R, Simonneau G; Task Force for the Diagnosis and Treatment

of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European

Respiratory Society (ERS). Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Heart

J. 2011 Feb;32(4):386-7. PubMed PMID: 21416695

114.Attinà D, Valentino M, Galiè N, Modolon C, Buia F, de Luca F, Bacchi-Reggiani ML, Zompatori M.

Application of a new pulmonary artery obstruction score in the prognostic evaluation of acute

pulmonary embolism: comparison with clinical and haemodynamic parameters. Radiol Med. 2011

Mar;116(2):230-45. doi: 10.1007/s11547-010-0613-1. Epub 2010 Dec 3. English, Italian. PubMed

PMID: 21311989.

115.Galiè N, Hoeper MM, Gibbs JS, Simonneau G. Liver toxicity of sitaxentan in pulmonary arterial

hypertension. Eur Respir J. 2011 Feb;37(2):475-6. doi: 10.1183/09031936.00194810. PubMed

PMID: 21282816.

116.Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N;

Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil

monotherapy and as add-on to background bosentan in patients with pulmonary arterial

hypertension. J Heart Lung Transplant. 2011 Jun;30(6):632-43. doi: 10.1016/j.healun.2010.11.009.

Epub 2011 Jan 21. PubMed PMID: 21256048.

117.Galie' N, Manes A, Palazzini M, Leci E (2011). Conventional Medical Therapies in the treatment of

pulmonary hypertension. In: PEACOCK A NAEIJE R RUBIN L. Pulmonary Hypertension. p. 303-313,

LONDON:Hadder Arnold, ISBN: 9780340981924

27

118.Galie' N, Manes A, Palazzini M., Leci E (2011). Pulmonary hypertension. In: TUBARO M. The ESC

Textbook of Acute and Intensive cardiac care. p. 650-659, OXFORD:Oxford University Press, ISBN:

9780199584314, doi: 10.1093/med/9780199584314.001.0001

119.Galiè, N., Rubin, L.J., Simonneau, G. To the editor (2010) New England Journal of Medicine, 362 (6),

pp. 559-560. DOI: 10.1056/NEJMc0912127

120.Galie' N, Manes A, Palazzini M (2011). Pulmonary Hypertension: Lessons from Adults. In: BEGHETTI

M. Pediatric Pulmonary Hypertension. p. 1-5, MUNICH:Elsevier

121.Sitbon O, Galiè N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of

using multiple goals. Eur Respir Rev. 2010 Dec;19(118):272-8. doi: 10.1183/09059180.00008210.

Review. PubMed PMID: 21119185.

122.Rossi A, Attinà D, Borgonovi A, Buia F, De Luca F, Guidalotti PL, Fughelli P, Galiè N, Zompatori M.

Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary

hypertension: could this evaluation replace lung perfusion scintigraphy? Eur J Radiol. 2012

Jan;81(1):e1-6. doi: 10.1016/j.ejrad.2010.09.032. Epub 2010 Nov 4. PubMed PMID: 21055892.

123.Galiè N, Palazzini M, Manes A. Pulmonary hypertension and pulmonary arterial hypertension: a

clarification is needed. Eur Respir J. 2010 Nov;36(5):986-90. doi: 10.1183/09031936.00038410.


124.Galiè N, Negro L, Simonneau G. The use of combination therapy in pulmonary arterial

hypertension: new developments. Eur Respir Rev. 2009 Sep;18(113):148-53. doi:

10.1183/09059180.00003809. Review. PubMed PMID: 20956135.

125.Manes A, Palazzini M, Galiè N. [Pulmonary hypertension and the relationships between

hemodynamic-pathophysiologic definitions, echocardiographic estimate and final clinical diagnosis:

clarification is needed]. G Ital Cardiol (Rome). 2010 May;11(5):408-11. Italian. PubMed PMID:

20860161.

126.Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA,

Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A,

Szatmari A, Thaulow E, Vouhe PR, Walma E; Task Force on the Management of Grown-up

Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European

Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the

management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010

Dec;31(23):2915-57. doi: 10.1093/eurheartj/ehq249. Epub 2010 Aug 27. PubMed PMID: 20801927.

127.Galiè N, Palazzini M, Leci E, Manes A. Current therapeutic approaches to pulmonary arterial

hypertension. Rev Esp Cardiol. 2010 Jun;63(6):708-24. PubMed PMID: 20515628.

128.Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-

dead to multiple clinical trial meta-analyses. Eur Heart J. 2010 Sep;31(17):2080-6. doi:

10.1093/eurheartj/ehq152. Epub 2010 May 26. PubMed PMID: 20504865; PubMed Central PMCID:

PMC2930983.

28

129.Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical worsening in trials of pulmonary

arterial hypertension: results and implications. Curr Opin Pulm Med. 2010 May;16 Suppl 1:S11-9.

doi: 10.1097/01.mcp.0000370206.61003.7e. Review. PubMed PMID: 20375660.

130.Galiè N, Rubin LJ, Simonneau G. Phosphodiesterase inhibitors for pulmonary hypertension. N Engl J

Med. 2010 Feb 11;362(6):559-60; author reply 560. PubMed PMID: 20175298.

131.Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD, Jais X, Schulze-Neick I, Galiè

N, Morganti A, Dingemanse J, Kusic-Pajic A, Berger RM. Pharmacokinetic and clinical profile of a

novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1

study. Br J Clin Pharmacol. 2009 Dec;68(6):948-55. doi: 10.1111/j.1365-2125.2009.03532.x.

PubMed PMID: 20002090; PubMed Central PMCID: PMC2805863.

132.Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD,

McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ; ARIES Study Group. Long-

term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol.

2009 Nov 17;54(21):1971-81. doi: 10.1016/j.jacc.2009.07.033. PubMed PMID: 19909879.

133.Developing new guidelines for the diagnosis and treatment of pulmonary hypertension. Galie N.

Eur Heart J. 2009 Oct;30(20):2416-8. PubMed PMID: 19842237.

134.Gruenig E, Michelakis E, Vachiéry JL, Vizza CD, Meyer FJ, Doelberg M, Bach D, Dingemanse J, Galiè

N. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan

therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin

Pharmacol. 2009 Nov;49(11):1343-52. doi: 10.1177/0091270009341182. Epub 2009 Sep 15.


135.Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S,

Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M,

Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Task Force

for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC);

European Respiratory Society (ERS); International Society of Heart and Lung Transplantation

(ISHLT), Eur Respir J. 2009 Dec;34(6):1219-63. doi: 10.1183/09031936.00139009. Epub 2009 Sep

12. PubMed PMID: 19749199.

136.Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial

hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell

Mol Physiol. 2009 Dec;297(6):L1013-32. doi: 10.1152/ajplung.00217.2009. Epub 2009 Sep 11.


137.Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine

S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M,

Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and

treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of

Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory

Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur

Heart J. 2009 Oct;30(20):2493-537. doi: 10.1093/eurheartj/ehp297. Epub 2009 Aug 27. Erratum in:

Eur Heart J. 2011 Apr;32(8):926. PubMed PMID: 19713419.

29

138.Manes A, Marinelli A, Palazzini M, Negro L, Leci E, Gambetti S, Bachetti C, Beciani E, Conficoni E,

Branzi A, Galiè N. [Pulmonary arterial hypertension. Part II: Medical and surgical treatment]. G Ital

Cardiol (Rome). 2009 Jun;10(6):366-81. Review. Italian. PubMed PMID: 19603608.

139.McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ,

Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End points and clinical trial design in

pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107. doi:


140.Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè

N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll

Cardiol. 2009 Jun 30;54(1 Suppl):S78-84. doi: 10.1016/j.jacc.2009.04.017. Review. PubMed PMID:

19555861; PubMed Central PMCID: PMC3686287.

141.Peacock AJ, Naeije R, Galiè N, Rubin L. End-points and clinical trial design in pulmonary arterial

hypertension: have we made progress? Eur Respir J. 2009 Jul;34(1):231-42. doi:

10.1183/09031936.00107108. Review. PubMed PMID: 19567606.

142.Palazzini M, Manes A, Negro L, Marinelli A, Leci E, Gambetti S, Bachetti C, Beciani E, Conficoni E,

Branzi A, Galiè N. [Pulmonary arterial hypertension. Part I: pathobiologic, pathophysiologic, clinical

and diagnostic aspects]. G Ital Cardiol (Rome). 2009 May;10(5):271-300. Review. Italian. PubMed

PMID: 19537440.

143.Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M,

Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil

(PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun

9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Erratum in:

Circulation. 2011 Sep 6;124(10):e279. Dosage error in article text. PubMed PMID: 19470885.

144.Torbicki, A., Perrier, A., Konstantinides, S., Agneli, G., Galiè, N., Pruszczyk, P., Bengel, F.,Brady,

A.J.B., Ferreira, D., Janssens, U., Klepetko, Guidelines on diagnosis and management of acute

pulmonary embolism [Orientações para o diagnóstico e tratamento da embolia pulmonar

aguda](2009) Revista Portuguesa de Cardiologia, 28 (5), pp. 569-614.

145.Berger RM, Beghetti M, Galiè N, Gatzoulis MA, Granton J, Lauer A, Chiossi E, Landzberg M. Atrial

septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of

pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Int J

Cardiol. 2010 Oct 29;144(3):373-8. doi: 10.1016/j.ijcard.2009.04.037. Epub 2009 May 21. PubMed

PMID: 19464064.

146.Grünig E, Weissmann S, Ehlken N, Fijalkowska A, Fischer C, Fourme T, Galié N, Ghofrani A, Harrison

RE, Huez S, Humbert M, Janssen B, Kober J, Koehler R, Machado RD, Mereles D, Naeije R,

Olschewski H, Provencher S, Reichenberger F, Retailleau K, Rocchi G, Simonneau G, Torbicki A,

Trembath R, Seeger W. Stress Doppler echocardiography in relatives of patients with idiopathic and

familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary

artery pressure response to exercise and hypoxia. Circulation. 2009 Apr 7;119(13):1747-57. doi:

10.1161/CIRCULATIONAHA.108.800938. Epub 2009 Mar 23. PubMed PMID: 19307479.

30

147.Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of

pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Mar 3;53(9):733-40. doi:


148.Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of

randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009 Feb;30(4):394-

403. doi: 10.1093/eurheartj/ehp022. Epub 2009 Jan 20. Review. PubMed PMID: 19155250;

PubMed Central PMCID: PMC2642921.

149.Galiè, N. The optical time to treat PAH patients. (2009) British Journal of Cardiology, 16 (SUPPL. 1),

pp. S10-S12.

150.Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady,

A.J.B., Ferreira, D., Janssens, U., Klepetko, Guidelines on the diagnosis and management of acute

pulmonary embolism [Linee guida per la diagnosi e il trattamento dell'embolia polmonare

acuta](2009) Giornale Italiano di Cardiologia, 10 (5), pp. 303-345.

151.Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G,

Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Addition of sildenafil to long-term

intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized

trial. Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan

6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435. PubMed PMID: 18936500.

152.Galiè, N., Simonneau, G. Bosentan in mild pulmonary hypertension - Authors' reply (2008) The

Lancet, 372 (9651), pp. 1731-1732. DOI: 10.1016/S0140-6736(08)61727-4

153.McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ,

Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial

hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

Chest. 2009 Jan;135(1):122-9. doi: 10.1378/chest.08-1028. Epub 2008 Sep 23. PubMed PMID:

18812445.

154.Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira

D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP; ESC Committee for Practice

Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the

Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European

Society of Cardiology (ESC). Eur Heart J. 2008 Sep;29(18):2276-315. doi: 10.1093/eurheartj/ehn310.

Epub 2008 Aug 30. PubMed PMID: 18757870.

155.Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin

L, Fleming TR, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year,

prospective, open-label observation of outcome and survival. Chest. 2008 Oct;134(4):775-82. doi:

10.1378/chest.07-0767. Epub 2008 Jul 14. Erratum in: Chest. 2009 Apr;135(4):1114. PubMed PMID:

18625676.

156.Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G.

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan

(EARLY study): a double-blind, randomised controlled trial. Lancet. 2008 Jun 21;371(9630):2093-

100. doi: 10.1016/S0140-6736(08)60919-8. PubMed PMID: 18572079.

31

157.Mikus PM, Mikus E, Martìn-Suàrez S, Galiè N, Manes A, Pastore S, Arpesella G. Pulmonary

endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results. Eur J

Cardiothorac Surg. 2008 Jul;34(1):159-63. doi: 10.1016/j.ejcts.2008.04.048. Epub 2008 Jun 12.


158.Galiè, N., Manes, A., Hirani, N., Naeije, R.Comparative Analysis of Clinical Trials and Evidence-Based

Treatment Algorithm for Pulmonary Arterial Hypertension

(2008) Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment, pp. 203-221.

DOI: 10.1002/9780470997390.ch10

159.Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD,

McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ; Ambrisentan in Pulmonary

Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies

(ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the

ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled,

multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10;117(23):3010-9. doi:

10.1161/CIRCULATIONAHA.107.742510. Epub 2008 May 27. PubMed PMID: 18506008.

160. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E, Donti A, Branzi A,

Picchio FM. Management of pulmonary arterial hypertension associated with congenital systemic-

to-pulmonary shunts and Eisenmenger's syndrome. Drugs. 2008;68(8):1049-66. Review. PubMed

PMID: 18484798.

161.Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G; SUPER Study Group.

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J

Rheumatol. 2007 Dec;34(12):2417-22. Epub 2007 Nov 1. PubMed PMID: 17985403.

162.Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M;

BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in

Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008

Jun 23;127(1):27-32. Epub 2007 Jul 20. PubMed PMID: 17658633.

163.Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, Paillette Ld, Zaccardelli D, Davis G,

Jeffs R, Simonneau G, Galie N. Rapid switch from intravenous epoprostenol to intravenous

treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2007

Jan;49(1):1-5. PubMed PMID: 17261956.

164.Galié, N., Manes, A., Palazzini, M., Negro, L., Romanazzi, S., Branzi, A.Pharmacological impact on

right ventricular remodelling in pulmonary arterial hypertension (2007) European Heart Journal,

Supplement, 9 (H), pp. H68-H74. DOI: 10.1093/eurheartj/sum055

165.Galiè, N., Hirani, N., Manes, A., Romanazzi, S., Palazzini, M., Negro, L., Branzi, A.Long-term

therapeutic outcomes in pulmonary arterial hypertension(2007) Current Medical Research and

Opinion, 23 (SUPPL. 2), pp. S11-S18. DOI: 10.1185/030079907X199484

166.Manes, A., Ferlito, M., Rocchi, G., Bacchi-Reggiani, L., Hirani, N., Romanazzi, S., Palazzini, M., Negro,

L., Branzi, A., Galiè, N. Left ventricular dimensions in pulmonary arterial hypertension:

32

Haemodynamic and exercise correlations (2007) Current Medical Research and Opinion, 23 (SUPPL.

2), pp. S55-S62.DOI: 10.1185/030079907X199547

167.Hirani, N., Manes, A., Parravicini, C., Scalamogna, C., Palazzini, M., Negro, L., Romanazzi, S., Longhi,

E., Bestetti, G., Piolin, R., Lunghi, G., Orlandi, Evidence for Kaposi's sarcoma-associated herpes virus

infection in patients with idiopathic pulmonary arterial hypertension: A case series and review

(2007) Current Medical Research and Opinion, 23 (SUPPL. 2), pp. S83-S87. DOI:

10.1185/030079907X199583

168.Gatzoulis, M.A., Barst, R., Fineman, J., Galiè, N. Eisenmenger syndrome and pulmonary arterial

hypertension in adults with congenital heart disease (2007) Current Medical Research and Opinion,

23 (SUPPL. 2), pp. S19-S25. DOI: 10.1185/030079907X199763

169.Donti A, Formigari R, Ragni L, Manes A, Galiè N, Picchio FM. Pulmonary arterial hypertension in the

pediatric age. J Cardiovasc Med (Hagerstown). 2007 Jan;8(1):72-7. Review. PubMed PMID:

17255821.

170.Grigioni F, Potena L, Galiè N, Fallani F, Bigliardi M, Coccolo F, Magnani G, Manes A, Barbieri A, Fucili

A, Magelli C, Branzi A. Prognostic implications of serial assessments of pulmonary hypertension in

severe chronic heart failure. J Heart Lung Transplant. 2006 Oct;25(10):1241-6. Epub 2006 Sep 7.


171.Rubin LJ, Hoeper MM, Klepetko W, Galiè N, Lang IM, Simonneau G. Current and future

management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment

responses. Proc Am Thorac Soc. 2006 Sep;3(7):601-7. Review. PubMed PMID: 16963541. DOI:

10.1513/pats.200605-111LR

172.Galiè N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary

hypertension. Proc Am Thorac Soc. 2006 Sep;3(7):571-6. Review. PubMed PMID: 16963536.

173.Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ. Long-term outcome in

pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006

Dec;28(6):1195-203. Epub 2006 Aug 9. PubMed PMID: 16899485.

174.Mikus PM, Dell'Amore A, Pastore S, Galiè N. Pulmonary endarterectomy: is there an alternative to

profound hypothermia with cardiocirculatory arrest? Eur J Cardiothorac Surg. 2006 Sep;30(3):563-

5. Epub 2006 Aug 1. PubMed PMID: 16884907.

175.Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M;

Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind,

randomized, placebo-controlled study. Circulation. 2006 Jul 4;114(1):48-54. Epub 2006 Jun 26.


176.Galiè, N., Rubin, L.J., Simonneau, G. The authors reply [15] (2006) New England Journal of

Medicine, 354 (10), pp. 1092-1093.

177.Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N; STRIDE-2

Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A

33

receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006 May 16;47(10):2049-56. Epub 2006 Apr 24.


178.Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N,

Manes A, Corris P, Simonneau G, Humbert M, Morrell NW, Trembath RC. BMPR2 gene

rearrangements account for a significant proportion of mutations in familial and idiopathic

pulmonary arterial hypertension. Hum Mutat. 2006 Feb;27(2):212-3. PubMed PMID: 16429403.

179.Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, Janssen B, Koehler

R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, Glissmeyer E, Carlquist J, Kim M, Torbicki A,

Fijalkowska A, Szewczyk G, Parma J, Abramowicz MJ, Galie N, Morisaki H, Kyotani S, Nakanishi N,

Morisaki T, Humbert M, Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell NW, Trembath RC.

Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat.

2006 Feb;27(2):121-32. PubMed PMID: 16429395.

180.Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G,

Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial

Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension.

N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.


181.Galiè N, Branzi A. Pulmonary arterial hypertension: therapeutic algorithm. Ital Heart J. 2005

Oct;6(10):856-60. Review. PubMed PMID: 16270480.

182.Galiè N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L, Romanazzi S, Branzi A. Pulmonary

arterial hypertension associated to connective tissue diseases. Lupus. 2005;14(9):713-7. Review.


183.Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ,

Simonneau G. Survival in patients with class III idiopathic pulmonary arterial hypertension treated

with first line oral bosentan compared with an historical cohort of patients started on intravenous

epoprostenol. Thorax. 2005 Dec;60(12):1025-30. Epub 2005 Jul 29. PubMed PMID: 16055621;

PubMed Central PMCID: PMC1747276.

184.Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R,

Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am

Coll Cardiol. 2005 Aug 2;46(3):529-35. PubMed PMID: 16053970.

185.Bertoni M, Niccoli L, Porciello G, Storri L, Nannini C, Manes A, Palazzini M, Galiè N, Cantini F.

Pulmonary hypertension in primary Sjögren's syndrome: report of a case and review of the

literature. Clin Rheumatol. 2005 Aug;24(4):431-4. Epub 2005 May 19. Review. PubMed PMID:

15906110.

186.Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A,

Pietra G, Rubin LJ, Simonneau G; Grupo de Trabajo sobre el diagnóstico y tratamiento de la

Hipertensión Arterial Pulmonar de la Sociedad Europea de Cardiología. [Guidelines on diagnosis

and treatment of pulmonary arterial hypertension]. Rev Esp Cardiol. 2005 May;58(5):523-66.

Spanish. PubMed PMID: 15899198. DOI: 10.1157/13074846

34

187.Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi A, Galié N. Antiproliferative

effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005

Mar;100(2):131-8. Epub 2004 Nov 24. PubMed PMID: 15739122.

188.McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ.

Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J.

2005 Feb;25(2):244-9. Erratum in: Eur Respir J. 2005 May;25(5):942. PubMed PMID: 15684287.

189.Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A,

Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers

J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA,

Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J; Task Force. Guidelines on diagnosis and

treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of

Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004

Dec;25(24):2243-78. PubMed PMID: 15589643.

190.Galiè N, Manes A, Branzi A. Evaluation of pulmonary arterial hypertension. Curr Opin Cardiol. 2004

Nov;19(6):575-81. Review. PubMed PMID: 15502501.

191.Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A,

Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension:

BREATHE-2. Eur Respir J. 2004 Sep;24(3):353-9. PubMed PMID: 15358690.

192.Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G; Treprostinil Study Group.

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with

connective tissue disease. Chest. 2004 Aug;126(2):420-7. PubMed PMID: 15302727.

193.Galiè N, Manes A, Branzi A. [New insights on pulmonary arterial hypertension]. Rev Esp Cardiol.

2004 Jul;57(7):603-7. Spanish. PubMed PMID: 15274843. DOI: 10.1157/13064184

194.Peacock A, Naeije R, Galié N, Reeves JT. End points in pulmonary arterial hypertension: the way

forward. Eur Respir J. 2004 Jun;23(6):947-53. Review. PubMed PMID: 15219011.

195.Rubin LJ, Galiè N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol. 2004 Jun

16;43(12 Suppl S):89S-90S. Review. PubMed PMID: 15194184. DOI: 10.1016/j.jacc.2004.02.030

196.Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and

evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004

Jun 16;43(12 Suppl S):81S-88S. Review. PubMed PMID: 15194183.

197.Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich

R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll

Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. Review. PubMed PMID: 15194173.

198.Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc

Res. 2004 Feb 1;61(2):227-37. Review. PubMed PMID: 14736539.

35

199.Galiè, N., Rubin, L.J. Introduction: New insights into a challenging disease: A review of the Third

World Symposium on Pulmonary Arterial Hypertension (2004) Journal of the American College of

Cardiology, 43 (12 SUPPL.). DOI: 10.1016/j.jacc.2004.03.003

200.Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med.

2003;2(2):123-37. Review. PubMed PMID: 14720012.

201.Torbicki A, Galié N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ; ICOPER Study Group. Right heart

thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism

Registry. J Am Coll Cardiol. 2003 Jun 18;41(12):2245-51. PubMed PMID: 12821255.

202.Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G,

Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I,

Rainisio M, Rubin L. Effects of the oral endothelin-receptor antagonist bosentan on

echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am

Coll Cardiol. 2003 Apr 16;41(8):1380-6. PubMed PMID: 12706935.

203.Galiè N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog

Cardiovasc Dis. 2002 Nov-Dec;45(3):213-24. Review. PubMed PMID: 12525997.

204.Galiè N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary

arterial hypertension. Eur Respir J. 2002 Oct;20(4):1037-49. Review. PubMed PMID: 12412701.

205.Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper

MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A,

Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized

Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug

1;347(5):322-9. PubMed PMID: 12151469.

206.Pereira, B.N., Salvi, S., Dietrich, C.G., Geier, A., Lammert, F., Rubin, L.J., Galiè, N., Simonneau, G.

Bosentan for pulmonary hypertension [3] (multiple letters) (2002) New England Journal of

Medicine, 347 (4), pp. 292-294.

207.Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L,

Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB,

Levy RD, Mehta S, Seeger W, Solèr M. Effects of the thromboxane synthetase inhibitor and

receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J. 2002

May;143(5):E4. PubMed PMID: 12040360.

208.Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension.

Am J Respir Crit Care Med. 2002 May 1;165(9):1209-16. Review. PubMed PMID: 11991870.

209.Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M,

Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G; Arterial Pulmonary Hypertension

and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin

analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-

controlled trial. J Am Coll Cardiol. 2002 May 1;39(9):1496-502. PubMed PMID: 11985913.

36

210.Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I,

Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med.

2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258. PubMed PMID:

11907289.

211.Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn

SD, Crow JW, Rubin LJ; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil,

a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind,

randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4.


212.Hoeper MM, Galié N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V,

Shapiro S, Pepke-Zaba J, Winkler J, Ewert R, Opitz C, Westerkamp V, Vachiéry JL, Torbicki A, Behr J,

Barst RJ. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial

hypertension. Am J Respir Crit Care Med. 2002 Feb 1;165(3):341-4. PubMed PMID: 11818318.

213.Galié N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin

Chest Med. 2001 Sep;22(3):529-37, x. Review. PubMed PMID: 11590846. DOI: 10.1016/S0272-

5231(05)70289-6

214.Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N,

Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M,

Wheeler L. Clinical and molecular genetic features of pulmonary hypertension in patients with

hereditary hemorrhagic telangiectasia. N Engl J Med. 2001 Aug 2;345(5):325-34. PubMed PMID:

11484689.

215.Galiè N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur Respir J. 2001

Jan;17(1):1-3. PubMed PMID: 11307737.

216.Zonzin, P., Torbicki, A., Van Beek, E.J.R., Charbonnier, B., Meyer, G., Morpurgo, M., Palla, A.,

Perrier, A., Galiè, N., Görge, G., Herold, C.J., Husted, Guidelines on diagnosis and management of

acute pulmonary embolism [Linee guida per la diagnosi ed il trattamento dell'embolia polmonare

acuta] (2001) Italian Heart Journal Supplement, 2 (2), pp. 161-199.

217.Galiè N, Torbicki A. Pulmonary arterial hypertension: new ideas and perspectives. Heart. 2001

Apr;85(4):475-80. Review. PubMed PMID: 11250981; PubMed Central PMCID: PMC1729670.

218.Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman

J, Williams D, Galiè N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M,

Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC. BMPR2

haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am

J Hum Genet. 2001 Jan;68(1):92-102. Epub 2000 Dec 12. PubMed PMID: 11115378; PubMed

Central PMCID: PMC1234937.

219.H J Dargie, P Lechat ,Klein W Brunhuber, R Hofmann, P Kühn, H-J Nesser, J Slany, W Weihsm, C

Wiedermann, H Wimmer. W van Mieghem, J Boland, J M Chaudron, L Jordaens, J P Melchior. CM

Aschermann, J Bruthansl, M Hradec, F Kölbel, B Semrád. T Haghfelt, J Fischer-Hansen, C O

Goetzsche, P Hildebrandt, E Kassis, V Rasmussen, J Rokkedal, A Thomassen. K Groundstroem, P

Uusimaa. J Y Le Heuzey, M C Aumont, J F Aupetit, N Baille, P Baudouy, A Belin, A Bonneau, G

Bonneric, J P Bousser, B Citron, P Dary, E Decoulx, P De Groote, T Denolle, F Dievart, P Duriez, J C

37

Eicher, G Enjuto, M Ferrière, E Fournier, M Garandeau, J Gauthier, M Genest, A Gerbe, J P Godenir,

B Guillot, J P Guillot, P Guillot, P Heno, C d'Ivernois, M Jean, S Kacet, R Kalle, M Komajda, A Lacroix,

R Lallemand, H Lardoux, M Marquet, M Martin, O Martin, D Méry, R Mossaz, P Mothes, T Olive, M

Ostorero, F Paganelli, E Page, C Pauly-Laubry, J Puel, J F Rousseau, J J Roux, A Schenowitz, K

Sourdais, F Tremel, A Verdun, S Witchiz, J E Wolf. V Hombach, I Assmann, T Beyer, K O Bischoff, H

Darius, G Ertl, E Fleck, K Förster, F Freytag, U Gleichmann, R Haasis, R Henβge, D Hey, P Hesse, T

Höfs, M Keck, H Klein, E T Kromer, J Krüls-Münch, B Lüderitz, B Maisch, V Mitrovic, S Neubauer, K J

Osterziel, H Simon, S G Spitzer, R Stöhring, G Taubert, W Teichmann, K Theisen, W Wende, H

Wieser, R Zotz. I Preda, M Csanády, L Cserhalmi, I Edes, T Gesztesi, P Kárpáti, K Simon, J Tarján. R

Fogari, R Tramarin, N Galie, P Giani, U Milanese, S Scalvini, D Scrutinio, L A Sechi, F Tettamanti, F De

Vito. P Crean, H McCann, D Mulcahy, D Sugrue. D C A van Hoogenhuyze, P H van der Burgh, R

Ciampricotti, J M van Dantzig, F R DenHartog, J A Henneman, HAM van Kesteren, J A Kragten, K L

Liem, A Limburg, M R van der Linde, G C M Linssen, H Pasteuning, H J A M Penn, P Van Rossum, H J

Schaafsma, A Schelling, R Sloos, JCL Wesdorp, J Korewicki, P Achremczyk, E Czestockowska, M

Dowgird, A Dyduszynski, J Górski, K Ilmurzynska, K Janicki, Z Kornacewicz-Jach, T Kraska, M

Krzeminska-Pakula, J Kuch, E Nartowicz, T Petelenz, W Piwowarska, I Rawczynska-Englert, W

Ruzyllo, G Swiatecka, M Tendera, M Wierzchowiecki, J Wodniecki, D Wojciechowoski, K Wrabec, H

Wysocki. R Seabra Gomes, M Fátima Ceia, N Lousada, J M Martins Campos, L A Providência, A L

Zamith Cerveira de Moura. V J Marejev, D M Aronov, G P Arutjunov, B J Bart, S S Basechikin, J N

Belenkov, J B Beloussov, O A Bokeria, R A Charchogljan, V Doschytsin, T A Fedorova, M G Glezer, A

Gorbachenkov, VA Gorshkov, A L Gospodarenko, V T Ivashkin, A J Ivleva, A A Kyrichenko, A A

Lavrov, L B Lazebnik, A Marynov, V P Mazaev, N R Polejev, A Shpektor, B A Sidorenko, K E Sobolev,

A K Starodoubtsev, G I Storozhakhov, A L Syrkin, V S Zodionchenko, T V Zvereva. J Murin, G Kaliská,

R Rybar. V Valle, M Artaza, P Conthe, J M Cruz, M Garcia-Moll, J L Lopez-Sendon, A Martinez, F

Monzón, M Ribas, E Roig. I Roldan C Höglund, S Ekdahl, L Hjelmaeus, K Lindberg, P Löfdahl, G

Ulvenstam, L Warselius. F Follath, W Anghern, P Dubach, P Erne, A Gallino, T Moccetti, A Bridges, J

Adgey, G Ambepitiya, N Boon, R M Boyle, A J Cowley, T Cripps, M K Davies, F Dunn, J Findlay, P

Forsey, T Fyfe, B Gould, T W Greenwood, P Hubner, S Khan, P Lewis, A Mackay, M Maltz, J

McArthur, A McLeod, D McLeod, M Metcalfe, M Millar-Craig, P Mills, J K Nelson, D Nicholls, G D

Oakley, D L H Patterson, J E F Pohl, S Ray, B Silke, P R Wilkinson. A V Jmouro. Reduced costs with

bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency

Bisoprolol Study (CIBIS-II). Eur Heart J. 2001 Jun;22(12):1021-31. PMID:11428837. DOI:

10.1053/euhj.2000.2532

220.Galiè N. Medical therapy of pulmonary arterial hypertension. Ital Heart J. 2000 Sep;1 Suppl 3:S110-

1. PubMed PMID: 11003038.

221.H J Dargie, P Lechat ,Klein W Brunhuber, R Hofmann, P Kühn, H-J Nesser, J Slany, W Weihsm, C

Wiedermann, H Wimmer. W van Mieghem, J Boland, J M Chaudron, L Jordaens, J P Melchior. CM

Aschermann, J Bruthansl, M Hradec, F Kölbel, B Semrád. T Haghfelt, J Fischer-Hansen, C O

Goetzsche, P Hildebrandt, E Kassis, V Rasmussen, J Rokkedal, A Thomassen. K Groundstroem, P

Uusimaa. J Y Le Heuzey, M C Aumont, J F Aupetit, N Baille, P Baudouy, A Belin, A Bonneau, G

Bonneric, J P Bousser, B Citron, P Dary, E Decoulx, P De Groote, T Denolle, F Dievart, P Duriez, J C

Eicher, G Enjuto, M Ferrière, E Fournier, M Garandeau, J Gauthier, M Genest, A Gerbe, J P Godenir,

B Guillot, J P Guillot, P Guillot, P Heno, C d'Ivernois, M Jean, S Kacet, R Kalle, M Komajda, A Lacroix,

R Lallemand, H Lardoux, M Marquet, M Martin, O Martin, D Méry, R Mossaz, P Mothes, T Olive, M

Ostorero, F Paganelli, E Page, C Pauly-Laubry, J Puel, J F Rousseau, J J Roux, A Schenowitz, K

Sourdais, F Tremel, A Verdun, S Witchiz, J E Wolf. V Hombach, I Assmann, T Beyer, K O Bischoff, H

Darius, G Ertl, E Fleck, K Förster, F Freytag, U Gleichmann, R Haasis, R Henβge, D Hey, P Hesse, T

38

Höfs, M Keck, H Klein, E T Kromer, J Krüls-Münch, B Lüderitz, B Maisch, V Mitrovic, S Neubauer, K J

Osterziel, H Simon, S G Spitzer, R Stöhring, G Taubert, W Teichmann, K Theisen, W Wende, H

Wieser, R Zotz. I Preda, M Csanády, L Cserhalmi, I Edes, T Gesztesi, P Kárpáti, K Simon, J Tarján. R

Fogari, R Tramarin, N Galie, P Giani, U Milanese, S Scalvini, D Scrutinio, L A Sechi, F Tettamanti, F De

Vito. P Crean, H McCann, D Mulcahy, D Sugrue. D C A van Hoogenhuyze, P H van der Burgh, R

Ciampricotti, J M van Dantzig, F R DenHartog, J A Henneman, HAM van Kesteren, J A Kragten, K L

Liem, A Limburg, M R van der Linde, G C M Linssen, H Pasteuning, H J A M Penn, P Van Rossum, H J

Schaafsma, A Schelling, R Sloos, JCL Wesdorp, J Korewicki, P Achremczyk, E Czestockowska, M

Dowgird, A Dyduszynski, J Górski, K Ilmurzynska, K Janicki, Z Kornacewicz-Jach, T Kraska, M

Krzeminska-Pakula, J Kuch, E Nartowicz, T Petelenz, W Piwowarska, I Rawczynska-Englert, W

Ruzyllo, G Swiatecka, M Tendera, M Wierzchowiecki, J Wodniecki, D Wojciechowoski, K Wrabec, H

Wysocki. R Seabra Gomes, M Fátima Ceia, N Lousada, J M Martins Campos, L A Providência, A L

Zamith Cerveira de Moura. V J Marejev, D M Aronov, G P Arutjunov, B J Bart, S S Basechikin, J N

Belenkov, J B Beloussov, O A Bokeria, R A Charchogljan, V Doschytsin, T A Fedorova, M G Glezer, A

Gorbachenkov, VA Gorshkov, A L Gospodarenko, V T Ivashkin, A J Ivleva, A A Kyrichenko, A A

Lavrov, L B Lazebnik, A Marynov, V P Mazaev, N R Polejev, A Shpektor, B A Sidorenko, K E Sobolev,

A K Starodoubtsev, G I Storozhakhov, A L Syrkin, V S Zodionchenko, T V Zvereva. J Murin, G Kaliská,

R Rybar. V Valle, M Artaza, P Conthe, J M Cruz, M Garcia-Moll, J L Lopez-Sendon, A Martinez, F

Monzón, M Ribas, E Roig. I Roldan C Höglund, S Ekdahl, L Hjelmaeus, K Lindberg, P Löfdahl, G

Ulvenstam, L Warselius. F Follath, W Anghern, P Dubach, P Erne, A Gallino, T Moccetti, A Bridges, J

Adgey, G Ambepitiya, N Boon, R M Boyle, A J Cowley, T Cripps, M K Davies, F Dunn, J Findlay, P

Forsey, T Fyfe, B Gould, T W Greenwood, P Hubner, S Khan, P Lewis, A Mackay, M Maltz, J

McArthur, A McLeod, D McLeod, M Metcalfe, M Millar-Craig, P Mills, J K Nelson, D Nicholls, G D

Oakley, D L H Patterson, J E F Pohl, S Ray, B Silke, P R Wilkinson. A V Jmouro. The Cardiac

Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13

PMID:10023943

222.Galiè N, Manes A, Uguccioni L, Serafini F, De Rosa M, Branzi A, Magnani B. Primary pulmonary

hypertension: insights into pathogenesis from epidemiology. Chest. 1998 Sep;114(3 Suppl):184S-

194S. Review. PubMed PMID: 9741567.

223.Ferlini A, Galié N, Merlini L, Sewry C, Branzi A, Muntoni F. A novel Alu-like element rearranged in

the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy.

Am J Hum Genet. 1998 Aug;63(2):436-46. PubMed PMID: 9683584; PubMed Central PMCID:

PMC1377294.

224.Magnani B, Galiè N. Prostacyclin in primary pulmonary hypertension. Eur Heart J. 1996

Jan;17(1):18-24. Review. PubMed PMID: 8682125.

225.Galiè N, Ussia GP, Catanzariti P, Grigioni F, Parlangeli R, Serafini F, Uguccioni L, Branzi A, Magnani B.

[Myocardial protection from ischemic damage: effects of preconditioning and pharmacologic

activation of KATP channels]. Cardiologia. 1995 Dec;40(12 Suppl 1):77-82. Review. Italian. PubMed

PMID: 8998785.

226.Galiè N, Guarnieri C, Ussia GP, Zimarino M, Traini AM, Parlangeli R, Vaona I, Branzi A, Magnani B.

Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs. J Cardiovasc

Pharmacol. 1995 Sep;26(3):477-84. PubMed PMID: 8583791.

39

227.Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the

treatment of primary pulmonary hypertension. Am J Cardiol. 1995 Jan 19;75(3):55A-62A. Review.


228.Bonow, R.O., Galiè, N., Gheorghiade, M., Magnani, B. Introduction (1995) The American Journal of

Cardiology, 75 (3 SUPPL. 1), pp. 1A-2A. DOI: 10.1016/S0002-9149(99)80376-2

229.Bonow, R.O., Galiè, N., Gheorghiade, M., Magnani, B. Conclusion. (1995) The American Journal of

Cardiology, 75 (3 SUPPL. 1), pp. 72A-73A. DOI: 10.1016/S0002-9149(99)80387-7

230.Fattori R, Rapezzi C, Castriota F, Magnani G, Bertaccini P, Galiè N, Magnani B, Gavelli G. [Clinical

significance of magnetic resonance and echocardiographic correlations in the evaluation of

hypertrophic cardiomyopathy]. Radiol Med. 1994 Jul-Aug;88(1-2):36-43. Italian. PubMed PMID:

8066253.

231.Rapezzi C, Fattori R, Castriota F, Passarelli P, Magnani G, Galiè N, Ferlito M, Bertaccini P, Branzi A,

Gavelli G, et al. [The role of magnetic resonance in studying hypertrophic cardiomyopathy: the

echocardiographic correlations and clinical implications]. Cardiologia. 1994 Jan;39(1):7-15. Italian.


232.Galiè N, Magelli C, Rapezzi C, Branzi A, Magnani B. [Vasodilator agents: the lesson from large

clinical trials]. Cardiologia. 1993 Dec;38(12 Suppl 1):221-6. Review. Italian. PubMed PMID: 8020020.

233.Rapezzi C, Assirelli C, Ortolani P, Ferlito M, Turinetto B, Fattori R, Galiè N, Castelli G, Branzi A,

Pierangeli A, et al. [Role of transesophageal echography in the diagnosis of aortic dissection and in

therapy programming]. Cardiologia. 1993 Nov;38(11):713-21. Italian. PubMed PMID: 8004643.

234.Galie N, Branzi A, Magnani G, Melandri G, Caldarera I, Rapezzi C, Grattoni C, Magnani B. Effect of

enoximone alone and in combination with metoprolol on myocardial function and energetics in

severe congestive heart failure: improvement in hemodynamic and metabolic profile. Cardiovasc

Drugs Ther. 1993 Jun;7(3):337-47. PubMed PMID: 8364004.

235.Magnani B, Rapezzi C, Galié N, Ortolani P. Use of multiple-action agents on the heart:

pathophysiological and therapeutic considerations. J Cardiovasc Pharmacol. 1992;19 Suppl 1:S44-9.


236.Branzi A, Melandri G, Galié N. [The management of postthrombolysis patients]. Cardiologia. 1991

Dec;36(12 Suppl 1):413-9. Review. Italian. PubMed PMID: 1688159.

237.Passarelli P, Galiè N, Limonetti P, Branzi A, Magnani B. [Comparative effects of doxazosin and

enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].

Cardiologia. 1991 Oct;36(10):777-83. Italian. PubMed PMID: 1686851.

238.Melandri G, Branzi A, Semprini F, Cervi V, Galiè N, Magnani B. Enhanced thrombolytic efficacy and

reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J. 1990

Aug;64(2):118-20. PubMed PMID: 2203397; PubMed Central PMCID: PMC1024350.

239.Galié N, Varani E, Maiello L, Boriani G, Boschi S, Binetti G, Magnani B. Usefulness of nicorandil in

congestive heart failure. Am J Cardiol. 1990 Feb 1;65(5):343-8. PubMed PMID: 2137279.

40

240.Galiè N, Metalli M, Zannoli R, Binetti G, Branzi A, Magnani B. Myocardial, coronary, and peripheral

effects of xamoterol (ICI 118,587) in open-chest pigs. Cardiovasc Drugs Ther. 1989 Mar;3(1):91-7.


241.Branzi A, Rapezzi C, Galiè N. [Beta-blocker therapy in heart failure: rational basis, indications,

dosages and cautions]. G Ital Cardiol. 1988 Dec;18(12):1072-9. Review. Italian. PubMed PMID:

2908108.

242.Branzi A, Galiè N, Metalli M, Rapezzi C. [Surgical indications in acquired tricuspid valvulopathies].

Cardiologia. 1988 Apr;33(4):347-52. Review. Italian. PubMed PMID: 3044587.

243.Melandri G, Branzi A, Berardi C, Bruscoli F, Tartagni F, Binetti G, Galiè N, Magnani B, Gensini GF,

Abbate R, et al. [Venous thrombolysis with the recombinant human tissue-type plasminogen

activator (rt-PA) during the first 3 hours following acute myocardial infarction. Controlled pilot

study with placebo]. Cardiologia. 1987 Jul;32(7):619-26. Italian. PubMed PMID: 3319156.

244.Branzi A, Galiè N, Specchia S, Binetti G, Ferretti RM, Berardi C, Magnani G, Zannoli R, Magnani B.

[Functional evaluation of heart insufficiency]. Cardiologia. 1986 Nov;31(11):955-61. Italian. PubMed

PMID: 3829071.

245.Seth L, Galiè N, Casebolt P, Gimenez H, Malloy M, Franciosa JA. Indoramin in heart failure: possible

adverse effects on hemodynamics and exercise capacity. Clin Pharmacol Ther. 1986 Nov;40(5):567-

74. PubMed PMID: 3769387.

246.Baker BJ, Leddy C, Galié N, Casebolt P, Franciosa JA. Predictive value of M-mode echocardiography

in patients with congestive heart failure. Am Heart J. 1986 Apr;111(4):697-702. PubMed PMID:

3953392.

247.Maresta A, Marzocchi A, Capucci A, Galiè N, Marrozzini C, Magnani B. Nifedipine compared with

verapamil in unstable angina pectoris. Int J Clin Pharmacol Res. 1986;6(4):291-301. PubMed PMID:

3759282.

248.Galiè N, Sanguinetti M, Marrozzini C, Magnani B. [Vasodilator therapy in chronic thromboembolic

cor pulmonare. Description of a case with unfavorable hemodynamic effects]. G Ital Cardiol. 1985

Oct;15(10):992-4. Italian. PubMed PMID: 4092919.

249.Galiè N, Magelli C, Ribani MA, Bassein L, Sanguinetti M, Magnani B. [Hemodynamic and clinical

effects of captopril in congestive heart failure]. G Ital Cardiol. 1985 Jan;15(1):70-9. Italian. PubMed

PMID: 3891488.

250.Marzocchi A, Ferretti RM, Galiè N, Magelli C, Marrozzini C, Magnani B. [Review of the criteria for a

positive electrocardiographic exercise test in 109 patients studied with coronary arteriography].

Minerva Cardioangiol. 1982 May;30(5):223-30. Review. Italian. PubMed PMID: 6752750.

251.Sanguinetti M, Galiè N, Magelli C, Orselli L, Magnani B. [Precapillary pulmonary hypertension:

effect of Captopril]. G Ital Cardiol. 1982;12(6):436-41. Italian. PubMed PMID: 6761221.

41

04 Marzo 2018 Prof. Nazzareno Galie'

Prof. Nazzareno Galiè - unibo.it€¦ ·

Documents

Transcript of Prof. Nazzareno Galiè - unibo.it€¦ ·